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ABSTRACT                                                          ENGLISH 
This doctoral thesis investigated different issues related to cognitive impairment (CI) in 
the nondemented elderly, including occurrence of CI, risk factors leading to CI 
development, and progression of CI to dementia. Data were derived from the 
Kungsholmen Project, a community-based study of 75+ years old (Studies II and IV), 
and from the HARMONY Study (Studies I and III), a nation-wide, population-based 
study of twins in Sweden. The major findings are summarized below. 
Study I. The prevalence of subjective cognitive impairment (SCI) and cognitive 
impairment no dementia (CIND) was estimated among nondemented elderly twins. 
Prevalence rates of SCI and CIND were 39 (38 to 39) and 25 (24 to 25) per cent. SCI 
was more prevalent among married people with higher education and socioeconomic 
status. A reverse pattern was observed in CIND. Both SCI and CIND were more 
prevalent among older compared to younger old. Probandwise concordance and 
tetrachoric correlations for SCI and CIND did not differ between monozygotic and 
dizygotic same-sex twins. 
Study II. The incidence of amnestic mild cognitive impairment (aMCI), other 
cognitive impairment no dementia (oCIND), and dementia was estimated using 9-year 
follow-up data. Incidence rates per 1,000 person-years of aMCI, oCIND and dementia 
were 11.4 (8.6 to 15.1), 33.8 (28.7 to 39.8), and 70.4 (64.0 to 77.4). Both aMCI and 
oCIND incidence increased with advancing age in a nonlinear fashion. When 
correcting for attrition due to death, the increase with age appeared more linear and 
was similar to that observed for dementia. 
Study III. The association of common chronic diseases with SCI and CIND was 
investigated, taking into account familial factors. In fully adjusted models, mental, 
musculoskeletal, respiratory, and urological diseases were associated with increased 
odds of both SCI and CIND. Gastrointestinal disorders were related to SCI, while 
endocrine diseases were associated with CIND. Multimorbidity was associated with 
100% and 50% increased odds of SCI and CIND, respectively. In co-twin control 
analyses, the chronic diseases-SCI association remained significant, but the 
association with CIND was largely attenuated. 
Study IV. Low mood was investigated in relation to aMCI and oCIND and their 
progression to dementia. People with low mood at baseline had a 2.7-fold (95% CI 1.9 
to 3.7) increased risk of developing MCI at follow-up. The association was stronger 
for aMCI (HR 5.8; 95% CI 3.1 to 10.9) compared with oCIND (HR 2.2; 95% CI 1.5 
to 3.3). Low mood at baseline was associated with a 5.3-fold (95% CI 1.2 to 23.3) 
increased risk of progression to dementia in aMCI. 
Conclusions. Cognitive impairment is highly frequent in the elderly population. Rates 
increase with age, especially when detected longitudinally and corrected for attrition. 
Other sociodemographic factors can also affect the distribution of CI among the 
nondemented. Co-morbid chronic diseases and multimorbidity are associated to 
increased odds of subjective and objective CI, while low mood is a strong predictor of 
CI development and progression in the cognitively healthy elderly. Familial factors 
contribute to non-dementia CI in a complex fashion. 
Key words: Attrition, chronic diseases, cognitive impairment no dementia, 
concordance, dementia, depressive symptoms, familial factors, incidence, low mood, 
mild cognitive impairment, multimorbidity, population-based, prevalence, prospective, 
sociodemographic factors, subjective cognitive impairment, twin study 
    
SAMMANFATTNING                                          SVENSKA 
Det övergripande syftet med denna avhandling var att studera faktorer som är relaterade 
till kognitiv nedsättning (CI) bland äldre personer utan demenssjukdom, samt att 
studera förekomst av CI, riskfaktorer för CI, samt riskfaktorer för demens hos personer 
med CI. Samtliga delstudier baseras på data från Kungsholmsprojektet, en 
befolkningsstudie med inriktning på personer 75 år och äldre (Studie II och IV), samt 
från HARMONY projektet (Studie I och III), en rikstäckande, populationsbaserad 
studie med svenska tvillingar.  
Studie I. I denna studie studerades prevalens av subjektiv kognitiv nedsättning (SCI) 
och kognitiv svikt utan demenssjukdom (CIND) bland icke-dementa tvillingpar. 
Prevalensen för SCI och CIND var 39 respektive 25 procent. SCI förekom oftare bland 
gifta personer med hög utbildning och hög socioekonomisk status. Det omvända 
mönstret observerades för CIND. Prevalensen för både SCI och CIND var högst bland 
de allra äldsta. Överenstämmelsen bland probandernas SCI och förekomsten av CIND 
skiljde sigej mellan monozygota och dizygota samkönade tvillingpar. 
Studie II. Incidens för amnestisk mild kognitiv nedsättning (aMCI), övriga kognitiva 
nedsättningar utan demenssjukdom (oCIND) och demens skattades med hjälp av en 
databas med 9 års uppföljning. Incidens per 1000 personer per år av aMCI, oCIND och 
demens var 11.4 (8.6-15.1), 33.8 (28.7-39.8), och 70.4 (64.0-77.4). Incidensen för både 
aMCI och oCIND ökade med åldern på ett ickelinjärt sätt. Vid korrigering för bortfall 
på grund av dödsfall uppfattades ökningen av incidens som mer linjär och mer lik den 
som observeras vid demenssjukdom. 
Studie III. Sambandet mellan vanliga kroniska sjukdomar och SCI och CIND 
undersöktes efter att ha kontrollerat för ärftliga faktorer. I justerade modeller var 
mentala, muskulära, respiratoriska och urologiska sjukdomar associerade med högre 
förekomst av SCI och CIND. Sjukdomar i mag- och tarmkanalen var i stor utsträckning 
relaterade till SCI medan endokrina sjukdomar var relaterade till CIND. 
Multimorbiditet var förknippad med fördubbladrisk för SCI samt 0.5 gånger ökad risk 
för CIND. I kontrollanalysen i tvillingstudien var associationen mellan kroniska 
sjukdomar och SCI fortfarande signifikant, men associationen till CIND var dock 
försvagad. 
Studie IV. Nedstämdhet undersöktes i relation till aMCI och oCIND samt deras 
progression till demens. Individer som led av nedstämdhet vid baslinjen hade 2.7 
gånger (95% CI 1.9-3.7) större risk att utveckla MCI vid uppföljning. Sambandet var 
starkare för aMCI (HR 5.8; 95% CI 3.1-10.9)  än för oCIND (HR 2.2; 95 CI 1.5-3.3). 
Nedstämdhet vid baslinjen var associerat med en 5.3 gånger (95% CI 1.2-23.3) ökad 
risk för progression till demens i aMCI. 
Slutsats. Kognitiv svikt förekommer ofta i den äldre populationen. Antalet drabbade 
ökar med åldern, särskilt när prevalensen uppmäts i longitudinella studier med 
korrigeringar för bortfall. Andra sociodemografiska faktorer kan också påverka 
fördelningen av kognitiv svikt bland äldre icke-dementa personer. Komorbida 
kroniska sjukdomar och multimorbiditet är associerade med ökad risk för subjektiv 
och objektiv kognitiv svikt, medan nedstämdhet predicerar utveckling av CI hos 
kognitivt friska äldre personer. 
Sökord: Attrition, befolkningsbaserad, demenssjukdom, depressiva symptom, 
familjära faktorer, incidens, kognitiv svikt, konkordans, kronisk sjukdom, mild 
kognitiv störning, multimorbiditet, nedstämdhet prevalens, prospektiv, 
sociodemografiska faktorer, subjektiv kognitiv störning, tvillingstudie 
  
SOMMARIO                                                         ITALIANO 
Questa tesi di dottorato ha investigato diversi aspetti associati al deterioramento 
cognitivo negli anziani non dementi, inclusi occorrenza del deterioramento cognitivo, 
l’esame dei suoi fattori di rischio e la progressione verso la demenza. I dati sono stati 
derivati dal Kungsholmen Project, uno studio sulla popolazione di 75 anni o più d’età 
(Studi II e IV) e dall’HARMONY Study (Studi I e III), uno studio in gemelli anziani su 
base nazionale. Di seguito i risultati principali: 
Studio I. La prevalenza del deterioramento cognitivo soggettivo (SCI) e del 
deterioramento cognitivo senza demenza (CIND) ѐ stata calcolata su una popolazione 
di gemelli anziani. Si ѐ rilevata una prevalenza del 39% (38-39%) e 25% (24-25%) per 
lo SCI ed il CIND. Contrariamente al CIND, lo SCI era più prevalente in persone 
sposate, di elevata educazione e condizione sociale. Sia SCI che CIND erano 
maggiormente prevalenti tra i più anziani. Tassi di concordanza e correlazioni 
tetracoriche non differivano tra gemelli monozigoti e dizigoti delllo stesso sesso. 
Studio II. L’incidenza del deterioramento cognitivo amnestico (aMCI), del 
deterioramento cognitivo di altro tipo (oCIND), e della demenza ѐ stata calcolata sulla 
base di 9 anni di osservazione longitudinale. I tassi d’incidenza per 1,000 persone-
anno di aMCI, oCIND e demenza erano 11.4 (8.6-15.1), 33.8 (28.7-39.8), e 70.4 
(64.0-77.4). L’incidenza sia dell’aMCI che dell’oCIND aumentava con l’avanzare 
dell’età in modo non lineare. Quando i tassi erano corretti per l’effetto della perdita di 
soggetti deceduti, l’aumento legato all’età appariva più lineare e maggiormente simile 
a quello osservato nella demenza. 
Studio III. L’associazione delle malattie croniche comuni con SCI e CIND ѐ stata 
investigata, prendendo in considerazione l’effetto di fattori familiari. In modelli 
completamente aggiustati, malattie mentali, muscolo-scheletriche, respiratorie e 
urologiche erano associate con un’aumentata probabilità sia di SCI che di CIND. I 
disordini gastrointestinali erano associati allo SCI, mentre le malattie endocrine erano 
associate al CIND. La polimorbidità era associata ad un aumento del 100% e 50% 
nella probabilita’ di SCI e CIND, rispettivamente. Nelle analisi con gemello di 
controllo, l’associazione tra malattie croniche e SCI rimaneva significativa, mentre 
l’associazione con il CIND era attenuata. 
Studio IV. L’umore depresso ѐ stato studiato in relazione all’aMCI e all’oCIND e alla 
loro progressione verso la demenza. Persone con umore depresso alla valutazione di 
base avevano un rischio 2.7 volte maggiore di sviluppare MCI alla visita di controllo. 
L’associazione era più forte per gli aMCI (HR 5.8; 95% CI 3.1-10.9) che per gli 
oCIND (HR 2.2; 95% CI 1.5-3.3). Negli aMCI, un umore depresso alla valutazione di 
base era associato ad un rischio 5.3 volte maggiore (95% CI 1.2-23.3) di progressione 
verso la demenza. 
Conclusioni. Il deterioramento cognitivo è molto frequente nella popolazione anziana 
senza demenza. I tassi aumentano con l’età, specialmente quando sono calcolati 
longitudinalmente, correggendo per l’effetto della perdita dei soggetti deceduti. Anche 
altri fattori sociodemografici possono influire sulla distribuzione del deterioramento 
cognitivo. La co-morbidità e la polimorbidità mediche sono associate a probabilità 
maggiori di deterioramento cognitivo soggettivo e oggettivo, mentre un umore depresso 
può predire sia lo sviluppo che la progressione a demenza del deterioramento cognitivo.   
Parole chiave: concordanza, demenza, deterioramento cognitivo, deterioramento 
cognitivo soggettivo, fattori familiari, fattori sociodemografici, incidenza, 
longitudinale, malattie croniche, polimorbidità, prevalenza, sintomi depressivi, studio di 
coorte, studio di popolazione, studio su gemelli, umore depresso 
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1 INTRODUCTION 
1.1 THE CHALLENGE OF GLOBAL AGING 
We are living longer. This represents one of the achievements of the last century but 
also a significant challenge. Indeed, a longer life expectancy requires careful planning 
from society, including clearly defined public health policies. In 2005 almost 500 
million people were age 65 and over, accounting for 8 percent of the world’s 
population. These figures are expected to increase to nearly 1 billion people aged 65 
and over by 2030, representing 12% of the world’s population.1, 2 While today’s 
proportions of elderly people are typically highest in more developed countries, the 
most rapid increases in older populations are occurring in the less developed world. 
Between 2006 and 2030, the number of older people in less developed countries is 
projected to increase by 140 percent as compared to an increase of 51 percent in more 
developed countries.1 These global changes are induced by the transition from a 
regime of high mortality and high fertility to a regime of low mortality and low 
fertility.3 The so called “demographic transition” has been described as a reduction of 
mortality leading to increased survival, particularly of children. 
 
 
Figure 1. Projected increase in global population between 2005 and 2030, by age (World 
Population Prospects, United Nations, 2005). 
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The reduced child mortality will in time lead to reduced fertility, because parents 
realize that a limited number of offspring can ensure the transferral of the genetic 
pool to the next generation. Sustained reduction of fertility slows down population 
growth and produces reduction of births.3 At the same time, lower mortality rates also 
promote a longer survival of the grown-up offspring, way beyond reaching adulthood. 
These two related mechanisms result in the disproportionally faster growth of older 
compared to younger population segments and result in an overall aging of the 
population. With time, these phenomena will lead to the progressive aging of the 
older population itself, with an increased proportion of older people living to 
increasingly advanced ages (Figure 1).1, 3 
1.2 ALZHEIMERS DISEASE AND THE DEMENTIAS 
A longer life is not necessarily a healthier life. Indeed, both at the individual and 
societal level, age-related diseases and disability represent the main challenges related 
to global aging. The Global Burden of Disease, a study conducted by the World 
Health Organization and the World Bank, predicted a very large increase in disability 
caused by age-related chronic disease in all regions of the world. As a consequence, 
chronic diseases, rather than infectious or childhood diseases and accidents, are 
becoming the major cause of loss of health and life worldwide.1 
Alzheimer’s disease (AD) represents one of the most common and invalidating 
chronic diseases of older age.4, 5 From a clinical and behavioral perspective, AD 
manifests itself as a series of symptoms and signs that are currently known as 
dementia. This syndrome is characterized by progressive deteriorations in multiple 
cognitive domains that are severe enough to interfere with daily functioning.6, 7 AD is 
the most common cause of dementia in the elderly, accounting for 60-70% of all 
demented cases.8, 9 AD is strictly related to a neuropathological diagnosis determined 
by the presence of neurofibrillary tangles and senile plaques in the brain of a patient 
with dementia.9 Vascular dementia (VaD) is the second most common cause of 
dementia in the elderly after AD. VaD is defined as loss of cognitive function 
resulting from ischemic, hypoperfusive, or hemorrhagic brain lesions due to 
cerebrovascular disease or cardiovascular pathology.10 The combination of AD and 
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VaD pathological changes in the brain of older people is extremely common, making 
mixed dementia probably the most common type of dementia.11 
1.2.1 Epidemiology 
Both prevalence and incidence of dementia rise with increasing age and dementia 
occurrence is relatively constant across different countries.12, 13 Several meta-analyses 
have resulted in similar estimates of dementia prevalence, notwithstanding differences 
in study designs and diagnostic criteria.14 The age-specific prevalence of dementia 
almost doubles every five years, from approximately 1.5% in persons aged 60-69 years 
to 40% in nonagenarians. The global dementia prevalence in people aged over 60 is 
3.9%, with the regional prevalence varying from 1.6% in Africa, 3.9% in Eastern 
Europe, 4.0% in China, 4.6% in Latin America, 5.4% in Western Europe, and 6.4% in 
North America.  There is a similar pattern in the distribution of dementia subtypes 
across the world, with the two most common forms of dementia, AD and VaD, 
accounting for 60-79% and 15-25% of all dementia cases, respectively.4 In Europe, the 
age-adjusted prevalence is 6.4% for dementia in general, 4.4% for AD, and 1.6% for 
VaD among people 65 years and older.15, 16 
Even dementia incidence does not show great geographical variation in the world. The 
global annual incidence of dementia is around 7.5 per 1,000 population. The incidence 
rate of dementia increases exponentially with age, from approximately one per 1,000 
person-years in people aged 60-64 years to more than 70 per 1,000 person-years in 90+ 
year-olds. The incidence rates of dementia across regions are quite similar in the 
younger-old (<75 years), but greater variations are seen among the older ages.4 Slightly 
lower rates have been detected in the USA in comparison with Europe and Asia, and 
this is possibly due to differences in the study designs and the case ascertainment 
procedures. 
It has been estimated that 24.3 million people have dementia today, with 4.6 million 
new cases of dementia every year. The number of dementia cases will double every 20 
years to 81.1 million by 2040.17 The highest number of people with dementia are in 
China (6 million), followed by the European Union (5 million), USA (2.9 million), and 
India (1.5 million). The rates of increase in the number of dementia cases are not 
uniform across the world; numbers in developed countries are expected to increase by 
Cognitive impairment in the nondemented elderly 
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100% between 2001 and 2040, but by more than 300% in India, China, and other south 
Asian and western Pacific countries.17 
1.2.2 Disease progression 
Once the diagnosis of dementia has been made, progression can be fast. It has been 
estimated that more than 50% of the dementia cases reach the severe stage within three 
years. A study form the Kungsholmen Project reported an increase in the proportion of 
severe dementia among prevalent cases from 19% at baseline to 48% after three years, 
and to 78% after seven years.18 This progression is due to both cognitive and functional 
decline. 
Dementia is strongly associated with disability and was the major determinant of 
functional dependence and decline over a three-year period. For approximately half of 
the persons who developed functional dependence over three years disability was 
attributable to dementia.19 In industrialised countries, mental disease and cognitive 
impairment are the most prevalent disorders among older adults living in nursing 
homes or other institutions. However, institutionalisation of dementia patients varies 
depending on age structure, urban or rural residence, and other cultural aspects. 
Dementia triples the risk of death.20 In a 75+ year old population, 70% of incident 
dementia cases die during the five years following the diagnosis, accounting for a 
mortality rate specific to dementia of 2.4 per 100 person-years. 
The demands of healthcare and social service of the huge and rapidly growing numbers 
of dementia patients have a major economic impact at societal levels.21 The worldwide 
direct costs of dementia in 2003 are estimated at 156 billion USD in the main scenario 
of a worldwide prevalence of 27.7 million demented persons. Due to these costs and 
the expected increase in the number of elderly people in developing countries, 
dementing conditions will present a great challenge.22 
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1.3 THE GREY AREA: COGNITIVE IMPAIRMENT WITHOUT DEMENTIA 
In recent years the focus of research in the field of aging and dementia has gradually 
shifted from dementia to syndromes of cognitive impairment (CI) in people without 
overt dementia. This shift was initially driven by the prospect of implementing 
pharmacological interventions at an early stage of AD, in order to postpone or prevent 
the onset of the disease.23 After the less than satisfying results of pharmacological 
trials on preclinical AD,23 the interest is moving toward even earlier stages of 
neurodegeneration, when the CI is not yet manifest and there is still room for 
preventative strategies.24, 25 The growing clinical and scientific work on early 
cognitive disorders has also made more and more apparent that the dementias are 
only the “tip of the iceberg” and that cognitive problems can represent, per se, an 
important target of prevention and possible therapeutic interventions.26, 27 Indeed, 
even mild cognitive deficits can have a strong impact on people’s lives and have 
important consequences at both a societal and public health level.28-31 
1.3.1 How to define it? 
Common to medical and epidemiological research is the definitional issue. In other 
words, once we have recognized the importance of a clinical and public health target 
we need to face the problem of reaching an agreement regarding a valid definition of 
the outcome of interest. This is extremely relevant in order to allow scientific findings 
to “sum up” and translate in recommendations and guidelines for the individuals 
concerned, the specialists working in the field and, last but not least, to determine 
public health policies. 
During the last 20 years, many definitions of cognitive impairment have been 
suggested. Among others, “Age-Associated Memory Impairment” (AAMI), “Ageing-
Associated Cognitive Decline” (AACD), “Age-Related Cognitive Decline” (ARCD), 
and “Mild Cognitive Disorder” (MCD), Mild Cognitive Impairment (MCI), and 
Cognitive Impairment No Dementia (CIND) have been put forward.32 All these 
definitions share the common aim of classifying non demented elderly into one of two 
possible categories, cognitively impaired or cognitively unimpaired. Notwithstanding 
the common purpose, these definitions differ in the set of behavioral signs used to 
identify non-dementia CI. Important differences can in fact be observed when 
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considering the definitional criteria of the two most widely-known labels, MCI and 
CIND. 
MCI. MCI’s original construct referred to a cluster of clinical symptoms that included: 
a) not being demented; b) reporting a memory complaint, preferably corroborated by an 
informant; c) having preserved general cognitive functioning; d) having preserved 
functioning in daily life activities; and e) showing objective memory impairment. In 
this first definition of MCI, the focus was on memory problems. Deficits in cognitive 
domains other than memory were allowed, but isolated deficits in non-memory 
domains were not included. Moreover, the criterion of “preserved general functioning” 
was often operationalized like scoring above a specific cut-off at a measure of global 
cognitive functioning, such as the Mini Mental State Examination (MMSE),33 which 
may have also excluded a proportion of people with deficits extended to other cognitive 
areas. The subsequent revision of MCI34 led to dismissal of the criterion of “preserved 
general functioning” and to define objective cognitive impairment as a deficit in any 
cognitive domain. In an attempt to differentiate different forms of MCI, the Mayo 
Clinic group proposed MCI sub-types that included two broader categories of 1) aMCI, 
and 2) non amnestic MCI (naMCI). Within aMCI and naMCI main categories, subjects 
can be further classified as: i) aMCI single, when deficits are limited to the memory 
domain; ii) aMCI multiple, when the deficits are extended to other cognitive domains; 
iii) naMCI single, when the deficits are limited to one non-memory domain; and iv) 
naMCI multiple, when the deficits are extended to multiple non-memory domains. 
CIND. CIND’s refers to any type of CI in nondemented persons. More specifically, 
CIND requires: 1) objective impairment as defined by cognitive tests; and 2) absence of 
dementia. Early definitions of CIND also required a “clinical judgement” of cognitive 
impairment.35-37 However, subsequent studies of CIND tended to omit this criterion, 
possibly due to the problematic issues of operationalization and reproducibility.38-41 
Although CIND subtypes are not widely used, attempts to create subcategories based 
on CIND severity38 and on the number of impaired domains41 have been made. 
The operationalization issue. Besides variations between different definitions of CI, 
there have also been differences in the operationalization of the same definition (Table 
1).42 First, as both MCI and CIND are dichotomous outcomes, one problem is where to 
set the boundary between normal and impaired cognitive functioning, i.e. the choice of 
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the cut-off. In medicine, statistical cut-offs are widely used to discriminate between 
biological values within the “norm” and “abnormal” values. In cognitive testing, the 
same type of reasoning is used to determine how far below the average a performance 
at a specific cognitive task has to fall to be considered impaired. Commonly used cut-
offs for both MCI and CIND are -1, -1.5, -2 SD from the mean, although percentiles-
based cut-offs have also been adopted (Table 1). Besides having an impact on the 
frequency of a disease, the choice of a specific cut-off can determine the severity of the 
cases included. An important aspect related to this issue is the choice of the normative 
population. It has recently been reported that using external versus local norms for 
cognitive tests can strongly influence the classification of cognitive impairment.43 
Secondly, another step in the operationalization of CI is to decide whether to consider 
differences in age and education when adjudicating cognitive scores. Indeed, these 
factors can affect cognitive test performance and lead to the (mis)classification of 
subjects who are “normal” -according to their age and educational level- in the 
cognitively impaired group. On the other hand, adjustment of cognitive scores by age 
and education evens out the effect of these important variables on cognitive 
impairment. 
Thirdly, regarding CIND operationalization, a set of different tests measuring specific 
cognitive functions can be used rather than a single measure of global cognitive 
functioning, such as the Mini Mental State Examination (MMSE).33 While the use of a 
test on global cognition may be handy, especially in large population-based studies, this 
type of measurement may (mis)classify as unimpaired milder cases of CI. 
Decisions taken at any of these levels will result in different frequencies and 
distributions of MCI and CIND and will strongly influence all epidemiological and 
clinical findings. 
1.3.2 Epidemiology 
The vast majority of epidemiological investigations on CI syndromes have used MCI 
and CIND definitions. The epidemiology of alternative definitions has been well 
summarized by Panza et al, 2005.32 
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1.3.2.1 Prevalence 
MCI. The prevalence of MCI ranges between 1 and 11.1 per cent (Figure 2), when 
considering estimates coming from population-based studies using the original or 
revised Mayo Clinic criteria for aMCI.44, 45 As shown in Figure 2, notwithstanding the 
relatively large interval, the majority (67%) of point estimates tend to fall between 
2% and 6%, presenting similarities even in the face of differences in the 
operationalization criteria (Table 1). On the other hand, age-specific prevalence 
estimates of MCI are affected by high variability, especially in the older age groups. 
As described in Figure 3, some studies detected an exponential increase with 
increasing age, but other studies reported no substantial increase. 
CIND. The prevalence of CIND ranges between 5.1% and 30% (Figure 4). An 
important source of variation is the use of both global and domain-specific cognitive 
measures of CIND (Table 1). Indeed, the highest prevalence of CIND has been 
reported by studies defining CIND as impairment on any cognitive task,37, 46 while 
intermediate prevalence estimates have been reported when using CIND definitions 
based on a global measure of cognitive functioning, such as the MMSE, and a non-
conservative cut-off of minus one standard deviation from the mean (Table 1).38, 47-49 
Notably, the lowest prevalence estimate of CIND comes from a study using a 
definition of CIND based on a measure of global cognitive functioning and a 
conservative cut-off of minus two standard deviations from the population mean 
(Figure 4, Table 1).39 Age-specific prevalence estimates of CIND are also 
characterized by high variability (Figure 5). In fact, out of eight studies, only five 
reported prevalence rates that increased with age and the increase was not always 
linear (Figure 5). 
Introduction 
9 
Figure 2. Prevalence per 100 of mild cognitive impairment (MCI) from major population-
based studies using original or revised Mayo Clinic criteria for amnestic MCI.45 Studies are 
described in Table 1. 
 
 
 
 
Figure 3. Age-specific prevalence per 100 of mild cognitive impairment (MCI) from major 
population-based studies using original or revised Mayo Clinic criteria for amnestic MCI.45 
Studies described in Table 1. 
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Figure 4. Prevalence per 100 of cognitive impairment no dementia (CIND) from major 
population-based studies. Studies are described in Table 1. 
 
 
 
 
Figure 5. Age-specific prevalence per 100 of cognitive impairment no dementia (CIND). 
Estimates from major population-based studies are shown. Studies are described in Table 1. 
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1.3.2.2 Incidence 
MCI. The incidence of MCI ranges between 8.5 and 25.9 per 1000 person-years 
(Figure 6), when considering estimates coming from population-based studies using 
the original or revised Mayo Clinic criteria for aMCI.44, 45 Although the variability 
appears high, it is reduced when excluding the two upper outliers, represented by 
estimates coming from studies with more inclusive criteria for MCI (Table 1). Indeed, 
in the ILSA study,50 memory impairment was defined as scoring within the lowest 
10th centile of the population distribution, while in CAIDE51 the definition of 
“preserved general cognitive functioning” was less conservative (MMSE scores (≥20) 
as compared to other investigations. Age-specific incidence rates have been reported 
by a limited number of studies and are characterized by high variability (Figure 7). In 
fact, out of four studies, half reported an exponential increase in incidence rates with 
increasing age, half reported no increase at all.  
CIND. There have been no population-based reports on the incidence of CIND. 
 
 
Figure 6. Incidence per 1000 person-years of mild cognitive impairment (MCI). Estimates 
from major population-based studies using original or revised Mayo Clinic criteria for 
amnestic MCI45 are shown. Studies are described in Table 1. 
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Figure 7. Age-specific incidence per 1000 person-years of mild cognitive impairment from 
major population-based studies using original Mayo Clinic criteria for amnestic MCI.45 Studies 
are described in Table 1. 
1.3.3 Correlates and risk factors 
Our current knowledge on correlates and risk factors for MCI and CIND derives mostly 
from population-based studies carried out in the last 10 years. Interest to this topic 
initially originated from a will to verify whether CI syndromes share the same risk 
factors as dementia. A positive answer to this question would support the idea that 
MCI/CIND is on the same continuum with dementia and that its prevention would 
result in effective dementia prevention. So far, we had only partial answers to this focal 
question. Current evidence shows a certain degree of overlap between MCI/CIND and 
dementia regarding correlates and risk factors. However, differences in risk profiles 
between dementia and MCI/CIND suggest that CI without dementia may be a distinct 
entity, susceptible to specific factors. So far, alike the dementias and even more so, the 
etiology of MCI/CIND appear to be multifactorial. Nonetheless, several possible 
candidate risk factors have been poorly investigated and available reports are often 
contradictory. 
1.3.3.1 Sociodemographic factors 
Age. The majority of population-based studies of MCI and CIND found a positive 
association with age, with an estimated excess risk between 4 and 800 per cent of 
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older compared to younger people (Table 2, Part A). Lower point estimates come 
from studies that considered age as a continuous rather than a dichotomous 
variable.50, 52 Notably, several studies did not find an association with age (Table 2, 
Part A). This may be due to the usual praxis of adjusting cognitive scores by age 
when defining MCI/CIND (see paragraph 1.3.1), which can attenuate the effect of 
age. 
Gender. The majority of studies found no effect of gender on MCI/CIND. Studies on 
CIND reported either increased odds in women or no effect of gender (Table 2, Part 
A). Findings on MCI are more difficult to interpret. Indeed, out of four studies that 
detected an association, half found men to be more at risk of MCI and the other half 
reported women to be the high risk gender (Table 2, Part A). It is possible that gender 
differences may play a less important role in MCI/CIND compared to dementia 
syndromes, where association with female gender has been consistently observed, at 
least after age 85.4 
Education. Studies on CIND reported either increased odds of CIND in less educated 
people or no effect of education (Table 2, Part A). Findings on MCI are less 
homogeneous, with some studies reporting higher odds of MCI in people with higher 
education. However, out of 21 studies investigating education in relation to 
MCI/CIND, 18 reported an association (Table 2, Part A). This suggests that, as 
previously observed for dementia,53 education is relevant also in MCI/CIND. Effects 
may be stronger than those reported, as cognitive tests are usually adjusted for 
education. 
Other sociodemographic factors. Only a few population-based studies of 
MCI/CIND investigated the association with socio-demographic factors other than 
age, gender, and education. The few available reports on marital status observed 
increased odds of CIND in unmarried persons,54-56 while studies of MCI found no 
effect at all.52, 54 Regarding socio-economic status (SES), available evidence suggests 
increased odds of both MCI and CIND in economically disadvantaged people.47, 55, 57 
Based on these limited data, marital status and SES appear to be relevant factors for 
SCI and CIND development and should be more thoroughly investigated. 
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1.3.3.2 Genetic factors 
APOE genotype is the only genetic factor that has been extensively studied in relation 
to MCI and CIND, although several other candidate susceptibility genes for dementia 
and AD could also be explored. 
APOE. The allelic ε4 variation of this genotype is a well-known risk factor for AD,58 
which is why research into MCI/CIND has focused on this gene. Almost all studies 
reported an association between APOE-ε4 and MCI (Table 2, Part B).51, 59-61 Findings 
using CIND as an outcome have been sparse (Table 2, Part B). In synthesis, APOE-ε4 
is relevant to the development of MCI and more research on this gene using the 
definition of CIND is warranted. 
1.3.3.3 Somatic diseases 
Current evidence on MCI/CIND and somatic conditions is based essentially on the 
role of vascular diseases, which have been investigated extensively, while other 
somatic disorders have received limited attention in relation to CI syndromes. 
Vascular Diseases. Stroke had no effect in studies using the MCI definition, although 
a differential role of this disease in men and women may be suspected (Table 2, Part 
B).62 In contrast, most studies on CIND reported an association with stroke,35, 55, 63 but 
more evidence coming from longitudinal studies is warranted (Table 2, Part B). 
Hypertension has been poorly investigated in relation to CIND and available evidence 
show no effect (Table 2, Part B).51, 55, 64 Out of seven large population-based studies 
on MCI and hypertension, only three reported a positive association,65, 66 while the 
rest found no effect (Table 2, Part B). Most studies investigating heart disease in 
relation to MCI/CIND found no effect. The only positive findings regard CIND (one 
out of three)35 and naMCI (Table 2, Part B).67 Finally, diabetes was associated to 
MCI/CIND in most investigations, although in two out of four studies reporting 
positive findings the association was present only in sub-groups, namely men and 
severe cases of diabetes (Table 2, Part B).62, 68 Overall, available evidence on vascular 
diseases and MCI/CIND has been contradictory, with more than half of the studies 
reporting no effect and with positive findings often limited to sub-groups. 
Other somatic diseases. Most evidence on the association between somatic diseases 
other than vascular come from investigations focused on specific cognitive functions 
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or on cognitive decline, rather than on cognitive impairment. Available findings 
suggest an association with several somatic diseases, such as hip fracture,64 asthma 
and COPD,69, 70 chronic kidney disease,71, 72 liver disease,73 thyroid dysfunction,74 and 
cancer.75, 76 Further investigations are warranted to confirm and expand these 
preliminary findings. 
1.3.3.4 Neuropsychiatric symptoms 
Neuropsychiatric symptoms are highly prevalent in MCI/CIND and have been the 
focus of several reviews77, 78 and investigations (Table 2, Part C). Depressive 
symptoms, anxiety and apathy have been the most widely studied symptoms. 
Depressive symptoms. Depressive symptoms have been extensively studied in 
relation to CI syndromes and have been consistently found associated to increased 
odds of both MCI and CIND. Indeed, out of six population-based cross-sectional 
investigations only one failed to find an association.79 Similarly, out of eight, 
population-based, longitudinal studies of depressive symptoms, six found a positive 
association with MCI/CIND (Table 2, Part C).60, 64, 80-82 Therefore, current evidence 
supports the view that depressive symptomatology often accompanies syndromes of 
CI and that cognitively healthy people with depressive symptoms are at increased risk 
of developing MCI/CIND. 
Anxiety. After depressive symptoms, anxiety has been the most studied 
neuropsychiatric symptom in CI syndromes. Nonetheless, evidence from population-
based investigations does not support the idea of increased levels of anxiety in 
MCI/CIND. In fact, only one83 out of six large studies reported increased odds of 
MCI in people with anxiety symptoms (Table 2, Part C). The lack of longitudinal 
investigations does not allow conclusions to be drawn on the role of anxiety in the 
development of MCI/CIND. 
Apathy. All three population-based studies reporting data on apathy found increased 
odds of both MCI and CIND in people with this symptom (Table 2, Part C).79, 83, 84 
However, similarly to anxiety, there are no longitudinal data on the progression to 
MCI/CIND in cognitively healthy people with apathy, therefore, its role as a possible 
risk factor for non-dementia CI is still unclear. 
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1.3.3.5 Environmental factors 
Environmental factors have been mostly studied in relation to specific cognitive 
domains or to cognitive decline rather than focusing on syndromes of CI.85-89 Also 
when cognitive impairment has been the chosen outcome, most investigations used ad 
hoc definitions, rather than common criteria for non-dementia CI, making results 
difficult to summarize. Available findings on MCI/CIND are often inconsistent and 
more research from population-based studies using current definitions is warranted. 
Smoking. One cross-sectional study reported decreased odds of CIND in relation to 
current cigarette smoking.35 A follow-up of the same cohort reported instead 
increased risk of MCI in frequent smokers compared to infrequent/non-smokers 
(Table 2, Part D).50 Other studies, both cross-sectional and longitudinal, found no 
effect of current or past cigarette smoking (Table 2, Part D). 
Diet. There is some evidence linking dietary habits with syndromes of CI. Increased 
risk of MCI were found in people reporting higher levels of saturated fat intake,90 
while higher levels of vegetables and polyunsaturated fat consumption were 
associated to reduced odds of MCI in cross-sectional investigations,91, 92 though not in 
longitudinal studies (Table 2, Part D).93, 94 The duration of the follow-up may be 
crucial to understand the effect of dietary factors on non-dementia CI. Indeed, the 
only longitudinal study reporting an association had a follow-up of 21 years (Table 2, 
Part D).90 
Alcohol. Out of five population-based studies, only one reported evidence of a 
protective effect of moderate alcohol drinking on rates of MCI.95 The same study 
reported increased odds of MCI in relation to past hazardous drinking, and this result 
was replicated by a cross-sectional study on CIND (Table 2, Part D).55 Overall, there 
is insufficient evidence to draw conclusions about the effect of moderate alcohol 
drinking on MCI/CIND. 
Exercise. Only a few studies have reported data on the relationship between physical 
exercise and non-dementia CI. Available longitudinal evidence suggests a protective 
effect of physical exercise on MCI/CIND development (Table 2, Part D).96-98 
Leisure Activities. Only two population-based longitudinal studies investigated 
leisure activities in relation to MCI/CIND. The study that reported a protective effect 
of leisure activities on MCI/CIND99 had a longer follow-up compared to the one that 
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found no effect (Table 2, Part D).64 
Social Isolation. This factor was associated to increased odds of MCI only in 
women,62 while no effect was found by a longitudinal study of CIND with a relatively 
short follow-up (Table 2, Part D).64 Longitudinal investigations with longer follow-up 
are warranted. 
1.3.4 Progression to dementia 
A potential area of investigation within dementia research has initially focused on the 
predictivity of MCI/CIND definitions for AD and dementia. Only recently some 
studies have focused on the identification of factors accelerating or promoting the 
progression of CI syndromes to dementia. As a consequence, the level of evidence for 
any of these factors is generally low. 
1.3.4.1 Progression rates and predictivity 
Cognitive impairment in nondemented elderly is one of the strongest risk factors for 
dementia. It has been estimated that over three years about one third of people with 
CIND will progress to dementia.38 A recent meta-analysis estimated that in people 
with MCI the combined relative risks of annual progression to AD and dementia are 
8.9 (95% CI 4.2-19.1) and 13.8 (95% CI 8.4-22.6).100 Averaging several large 
population-based studies, the annual conversion rates of MCI to AD and dementia 
were 6.8% (95% CI 1.9-14.5%) and 4.9% (95% CI 1.6-9.9%), respectively.100 These 
figures clearly show that only a proportion of people with MCI/CIND will progress to 
more advanced stages of CI, while others will remain stable or even improve.38 This 
phenomenon has led to several attempts to increase the predictivity of MCI/CIND for 
AD and dementia. In a study from the Kungsholmen Project, a three-step procedure 
resulted in a sensitivity of 48-50% and a specificity of 89-92% for people with both 
subjective memory complaints and impairment on episodic memory or verbal fluency 
tasks. However, only 18% of future dementia cases were identified by this diagnostic 
procedure.101 A recent study on primary care patients reported a sensitivity of 79.6% 
and a specificity of 66.4%, a positive predictive value (PPV) of 14.7% and a negative 
predictive value (NPV) of 97.8% by combining MMSE, episodic memory, and verbal 
fluency scores with other indicators such as subjective cognitive impairment, age, and 
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performance on instrumental activities of daily living (IADL).102 Different biological 
markers have also been tested as possible predictors of dementia in MCI/CIND103. In 
the last few years cerebrospinal fluid (CSF) concentrations of CSF-tau and Aβ-42 
have been studied extensively in relation to MCI104. However, it has been estimated 
that adding cerebrospinal fluid (CSF) biomarkers to bedside cognitive tests can 
reduce the misclassification rate in MCI from 38% to 30-24%, resulting in a relative 
improvement of merely 20-36% in accuracy.105 Thus, the relatively little 
improvement in the prognostic value of MCI does not support the routine use of these 
expensive and not always widely available diagnostic techniques. The use of imaging 
markers appears more promising,103 although studies have been characterized by high 
variability106 and it is still under debate which technique may be the most predictive 
and suitable in CI syndromes.107, 108 
1.3.4.2 Risk factors for progression to dementia 
The fact that MCI/CIND definitions do not have a high PPV has negative consequences 
on our capacity to identify those subjects that will develop dementia. However, low 
PPV also implies that there are factors that can promote or prevent progression to AD 
and dementia in people manifesting syndromes of CI. The positive aspects are that 
some of these factors may be modifiable and that non-modifiable risk factors can help 
in identifying MCI/CIND people at higher risk of progressing toward AD and 
dementia.109 The majority of available evidence on risk factors for progression to 
dementia in nondemented people with CI comes from relatively small clinic-based 
studies using the definition of MCI. 
Sociodemographic factors. Age strongly influences dementia risk in MCI62, 110-112 
and is included in risk indexes for the progression of MCI to dementia.109, 113 In a 
clinic-based study evaluating the 10-year risk of dementia of people with MCI age 
strongly influenced progression risk, which ranged from 0-0.06, in subjects aged 40 
to 54 years, to 0.77-1.0, in subjects aged 70 to 85 years. Lower education has also 
been found to be associated to accelerated progression from MCI to dementia.62, 111 
There is insufficient evidence regarding an effect of gender on MCI progression rates, 
however, men and women with MCI were found to have different risk profiles for 
dementia.62 
Genetic factors. APOE gene has been studied quite extensively in relation to the 
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progression of MCI to dementia, with inconsistent findings. Indeed, while the 
majority of longitudinal studies that examined the role of APOE-ε4 on MCI 
progression reported no effect,111, 114-117 some investigations found a positive 
association.62, 118, 119 Other genes possibly involved in the evolution of MCI are 
CHRNA7, ACT, and MAPT.117, 118 
Vascular Diseases. Stroke was the only vascular factor associated to the progression 
of MCI to dementia in a population-based prospective study.50 The relevance of 
stroke in MCI progression is only partly confirmed,62, 120 as several other 
investigations did not find an association.110, 114, 121 Atrial fibrillation was associated 
to an almost 5-fold increased risk of progression to dementia in a clinic-based study 
on MCI.122 However, this result has not yet been replicated. Diabetes was not 
associated to accelerated progression of MCI to dementia in two out of three 
population-based studies.50, 62, 123 In synthesis, evidence of the role of vascular diseases 
in MCI/CIND progression to dementia is contradictory. On the other hand, there is 
consistent evidence on the association of vascular cerebral lesions, such as 
periventricular and white matter hyperintensities, and increased risk of dementia in 
MCI. However, this association has been observed for vascular and mixed dementia but 
not for AD,124-126 with the exception of findings from a case-crossover study on white 
matter lesions.127 
Other somatic diseases. Non vascular somatic diseases have been investigated 
sparsely in relation to the progression of MCI/CIND to dementia. 
Neuropsychiatric symptoms. Depressive symptoms have been extensively studied as 
possible risk factors for dementia in people with MCI/CIND, but results are 
contradictory. Out of 10 longitudinal studies, three found that depressive symptoms 
increased the risk of progressing to dementia;128-130 two reported an association only 
in women or for isolated symptoms;62, 131 three found no association;132-134 and two 
recent studies reported that the presence of depressive symptoms decreased the risk of 
developing dementia.135, 136 Therefore, it is not currently possible to draw conclusions 
as to the role of depressive symptoms on the progression of MCI/CIND to dementia. 
Anxiety. There is limited evidence on the role of anxiety symptoms in the progression 
of CI syndromes. One population-based study reported increased risk of AD in MCI 
with anxiety symptoms at baseline.133 Apathy. A clinic-based study showed increased 
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baseline prevalence of apathy symptoms in MCI that later progressed to AD.137 To 
support this finding, two other studies, one hospital-based136 and one population-
based, reported increased risk of AD and dementia in MCI with symptoms of 
apathy.138 These preliminary findings, yet to be confirmed, suggest a possible role of 
apathy in the progression of MCI/CIND to dementia and AD. 
Environmental factors. Environmental factors have been studied very sparsely in 
relation to the progression of MCI/CIND to dementia. Available evidence suggest 
moderate alcohol consumption139 and adherence to a Mediterranean diet94 as possible 
protective factors. The promising results on the protective effect of physical exercise 
on rates of cognitive decline87 should be replicated in studies focusing on the 
evolution of CI syndromes. 
1.4 FROM PRE-DEMENTIA TO PRE-COGNITIVE IMPAIRMENT 
It is currently recognized that AD and dementia can be preceded by a long pre-clinical 
stage when functional impairment is not yet manifest and even cognitive deficits may 
not be detectable.24, 140-142 
1.4.1 Subjective cognitive impairment 
In their model of cognitive aging, Reisberg et al. (2008)140 hypothesize a stage of pre-
MCI, of an approximate duration of 15 years, characterized by subjective cognitive 
impairment (SCI) in the absence of objective cognitive deficits. Longitudinal studies 
support the idea that a proportion of people that will later develop dementia pass 
through a stage when cognitive deterioration is not yet evident but there is the 
subjective perception of a worsening in cognitive functioning.143, 144 This model of 
cognitive decline is promising. However, reality may be more complex. Indeed, as 
previously observed for MCI/CIND, not all people with SCI progress to dementia and 
some persons SCI will not even evolve into a non-dementia CI syndrome.143-145 
Notwithstanding the variability in the possible outcomes of SCI, its impact at the 
individual and societal level may be important. It has been reported that people with 
subjective cognitive complaints have a worse scores on quality of life measures146 and 
that these effects can persist over time.147 People with cognitive complaints are also 
likely to seek for help for their problems through the health care system, with a reported 
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60% increase in health care utilization over a three-year period,148 and/or using self-
prescribed medications, including vitamins and nutraceuticals.149 
1.4.1.1 Epidemiology, risk factors, progression 
The great majority of information on SCI comes from cross-sectional studies that did 
not exclude cognitive impairment, or even dementia, from SCI definition.141 This 
makes it difficult to generalize available findings to the current concept of SCI, which 
does not include objective cognitive deficits.  
Epidemiology.  Estimated prevalence of cognitive complaints is between 25 and 57 per 
cent.145, 150-153 No population-based study has reported data on the prevalence of SCI 
without cognitive impairment. Also, no study reported data on the incidence of SCI 
with or without CI. 
Correlates and risk factors. Studies on subjective cognitive complaints repeatedly 
showed association with older age.145, 150-155 The majority of reports also found 
association with female gender 151-153, 156  and low education.151, 153, 155, 157, 158 These 
results may not be generalizable to SCI without objective deficits. Indeed, the few 
studies that excluded cognitive impairment from the definition of SCI reported 
association with male gender159 and high education.160 Specific personality traits have 
been related to cognitive complaints.161-164 The important contribution of affective 
symptoms, such as depressed mood and anxiety, is generally acknowledged.140, 145, 159, 
164, 165 APOE-ε4 allele has also been associated to cognitive complaints.166-168 Other 
factors that have been associated to cognitive complaints are poor physical health and 
pain.153, 161, 169-171 
Progression to objective cognitive impairment and dementia. Only recently SCI 
without CI has started to be studied longitudinally, with the aim to evaluate the 
progression to syndromes of objective CI and dementia.143, 144, 172 In particular, in a 
large study on primary care patients, subjects with SCI at baseline and MCI at the 1 and 
½ year follow-up had an almost 9-fold increased risk of dementia at the 3-year follow-
up, compared to a two-fold increased risk of dementia in people with SCI that 
progressed to dementia without a detectable MCI stage, and to a 4-fold increased risk 
of dementia in people without SCI at baseline but with MCI at the 1 and ½ year visit.143 
A study on healthy volunteers with a follow-up of almost seven years reported a 4.5 
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increased risk of MCI or dementia in people with SCI at baseline.144 The only 
longitudinal population-based study on SCI without objective CI (follow-up time: 9 
years) found a 2-fold and a 1.5-fold increased risk of AD in people with higher and 
lower education and SCI at baseline.172 This latter evidence suggests that SCI may be 
an important first sign of imminent AD, especially in persons with a high level of 
education who still perform well on formal cognitive tests.172 Evidences from studies 
investigating cognitive complaints regardless of the presence/absence of objective 
cognitive impairment have been contradictory.145, 164, 173 More community-based studies 
are warranted to further explore the natural history of SCI in cognitively healthy 
persons.  
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Table 1. Operationalization criteria for MCI and CIND in the studies described in Figures 2 to 7. 
Study Author, year Age (yrs) 
Study 
Pop. Def Operationalization Reference Cut-off MI Cut-off CI 
CSHA  
 
(a)            Ebly et al,1995174 65+ 2,914 CIND Impairment at any test External NA Not specified 
                         (b) Graham et al, 199736 65+ 2,914 CIND As above As above NA As above 
 (c) Fisk et al, 2003175 65+ 1,790 MCI Original Mayo criteria45 As above Not specified NA 
KP                    (a) Palmer et al, 200238 75+ 1,435 CIND Global CI Local NA -1 SD 
                        (b) Palmer et al, 2008176 75+ 379 MCI MCI amnestic44, 45 Local -1.5 SD -1 SD 
LEILA 75+  (a) Busse et al, 2003177 75+ 1,045 MCI Original Mayo criteria45 Local -1 SD SIDAM  < 1 SD 
 (b) As above 75+ 1,045 MCI As above As above -1.5 SD  As above 
 (c) As above 75+ 1,045 MCI As above As above -2 SD  As above 
 (d) Luck et al, 2010178 75+ 1,692 MCI MCI amnestic44, 45 Local -1 SD  NA 
MYHAT  Ganguli et al, 2010179 65+ 1,982 MCI MCI amnestic44, 45 External Not specified Not specified 
Tone Town Study (a) Sasaki et al, 200959 65+ 1,433 MCI MCI amnestic44, 45 Local -1 SD  NA 
 (b) As above 65+ 1,433 MCI As above  -1.5 SD  As above 
PAQUID  Larrieu et al, 2002180 65+ 1,265 MCI Original Mayo criteria45 Local -1.5 SD  -1 SD 
Eugeria Study  Ritchie et al, 2001181 60+ 833 MCI Original Mayo criteria45 External Not specified Not specified 
MoVIES  Ganguli et al, 2004110 65+ 1,248 MCI Original Mayo criteria45 Local -1.5 SD  MMSE < 24 
CSBA  Ravaglia et al, 2008182 65+ 1,016 MCI MCI amnestic44, 45 Local -1.5 SD  NA 
Taijry Project  Meguro et al, 2004183 65+ 1,654 MCI Original Mayo criteria45 Local -1.5 SD  Not specified 
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Table 1 (continued). 
Study  Author, year Age 
(yrs) 
Study 
Pop. 
Def. Operationalization Reference Cut-off MI Cut-off CI 
Vecchiano Study (a) Tognoni et al, 2005184 65+ 1,600 MCI Original Mayo criteria45 External Not specified Not specified 
 (b) Marengoni et al, 201136 60-98 1,012 CIND Global cognitive impairment Local NA -1 SD 
CAIDE (a) Kivipelto et al, 2001185 65-79 1,449 MCI Original Mayo criteria45 Local -1.5 SD  MMSE < 20 
 (b) Hanninen et al, 2002163 60-76 806 MCI As above As above As above As above 
 (c) Tervo et al, 200451 60-76 747 MCI As above As above As above As above 
HNRSC  Dlugaj et al, 2010186 50-80 4,145 MCI MCI amnestic44, 45 Local -1 SD  NA 
Ariadna Study (a) Gavrila et al, 200948 65-96 1,074 MCI MCI amnestic44, 45 Local -1.5 SD  NA 
 (b) As above 65-76 1,074 CIND Global cognitive impairment  Local NA. -1 SD  
South Korea Study  Kim et al, 201157 65+ 1,673 MCI MCI amnestic44, 45 Local -1.5 SD  NA 
Mayo Study  Petersen et al, 201052 70-89 1,969 MCI MCI amnestic44, 45 Local -1 SD  NA 
Faenza Project  De Ronchi et al, 200539 60+ 7,930 CIND Global cognitive impairment  Local NA -2 SD 
Tayuan Study  Fei et al, 200954 65+ 6,192 CIND Impairment at any test External NA Not specified 
ILSA (a) Di Carlo et al, 200035 65-84 3,425 CIND Impairment at any test External NA Not specified 
 (b) Solfrizzi et al, 200450 65-84 2,963 MCI Original Mayo criteria45 Local Lower 10th centile MMSE<1.5 
North Portugal 
Arouca 
 
(a) 
 
Nunes et al, 200949 
 
55-79 
 
713 
 
CIND 
 
Global cognitive impairment  
 
Local 
 
NA 
 
-1 SD  
Sao João da 
Madeira 
(b) As above 55-79 433 CIND As above As above As above As above 
ISHA  Unverzagt et al, 200137 65+ 2,212 CIND Impairment at any test Local NA Lower 7th centile 
Porto Alegre Study  Chaves et al, 2009187 60+ 345 MCI MCI amnestic44, 45 Local -1.5 SD NA 
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Table 2, Part A. Major population-based studies concerning sociodemographic factors in relation to cognitive impairment no dementia (CIND) and mild cognitive 
impairment (MCI): Odds ratios (OR) or relative risk (RR) with 95% confidence intervals (CIs) are shown. 
Factors Author, year Study, Country Age (yrs) 
Study 
Pop. 
 
Case-
finding 
 
F-up 
(yrs) 
CI 
Definition Association; RR/OR 
Age                       Graham, 199736 CSHA, Canada 65+ 2,914 Prevalent NA CIND Positive 
 Di Carlo, 200035 ILSA, Italy 65-84 3,425 Prevalent NA CIND Positive; 1.09, 1.06-1.12  
 Frisoni, 200063 KP, Sweden 75+ 1,435 Prevalent NA CIND No effect 
 Unverzagt, 200137 ISHA, USA 65+ 2,212 Prevalent NA CIND No effect 
 De Ronchi, 200539 Faenza Project, Italy 60+ 7,930 Prevalent NA CIND No effect 
 Fei, 200954 Taiyuan Study, China 65+ 6,192 Prevalent NA CIND Positive 
 Gavrila, 200948 Ariadna Study, Spain 65-96 1,074 Prevalent NA CIND No effect 
 Hanninen, 2002163 CAIDE, Finland 60-76 806 Prevalent NA MCI Positive 
 Busse, 2003188 LEILA 75+, Germany 75+ 1,045 Prevalent NA MCI No effect 
 Ganguli, 2004110 MoVIES, USA 65+ 1,248 Prevalent NA MCI Positive; 1.04, 1.01-1.08  
 Solfrizzi, 200450 ILSA, Italy 65-84 2,963 Prevalent NA MCI Positive; 5.93, 3.17-11.10 
 Meguro, 2004183 Tajiri Project, Japan 65+ 1,501 Prevalent NA MCI No effect 
 Tognoni, 2005184 Vecchiano Study, Italy 65+ 1,600 Prevalent NA MCI Negative; 0.44, 0.28-0.69  
 Artero, 200862 3-C Study, France 65+ 6,892 Prevalent NA MCI Positive in men: 1.02, 1.01-1.04 
 Ravaglia, 2008182 CSBA, Italy 65+ 1,016 Prevalent NA MCI Positive 
 Nie, 2010189 Meta-analysis, China 60+ 43,430 Prevalent NA MCI Positive 
 Petersen, 201052 Mayo Study, USA 70-89 1,969 Prevalent NA MCI Positive; 2.31, 1.79-2.99  
 Larrieu, 2002180 PAQUID, France 65+ 2,084 Incident 5 MCI No effect 
 Busse, 2003177 LEILA 75+, Germany 75+ 1,045 Incident 2.6 MCI No effect 
 Solfrizzi, 200450 ILSA, Italy 65-84 2,963 Incident 3.5 MCI Positive; 8.16 4.02–15.61 
 Tervo, 200451 CAIDE, Finland 60-76 747 Incident 3 MCI Positive; 1.08, 1.01-1.15 
 Ravaglia, 2008182 CSBA, Italy 65+ 1,016 Incident 4 MCI No effect 
 Luck, 2010178 LEILA 75+ 75+ 1,692 Incident 8 MCI Positive; 1.06, 1.02-1.14 
 Unverzagt, 201180 ISHA, USA 65+ 1,668 Incident 5 MCI Positive 
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Table 2, Part A (continued). 
Factors Author, year Study, Country Age (yrs) 
Study 
Pop. 
 
Case-
finding 
 
F-up 
(yrs) 
CI 
Def. Association; RR/OR 
Gender, woman Graham, 199736 CSHA, Canada 65+ 2,914 Prevalent NA CIND No effect 
 Di Carlo, 200035 ILSA, Italy 65-84 3,425 Prevalent NA CIND Positive 
 Frisoni, 200063 KP, Sweden 75+ 1,435 Prevalent NA CIND No effect 
 Unverzagt, 200137 ISHA, USA 65+ 2,212 Prevalent NA CIND Positive 
 De Ronchi, 200539 Faenza Project, Italy 60+ 7,930 Prevalent NA CIND No effect 
 Fei, 200954 Taiyuan Study, China 65+ 6,192 Prevalent NA CIND Positive 
 Gavrila, 200948 Ariadna Study, Spain 65-96 1,074 Prevalent NA CIND Positive; 1.53, 1.06–2.22 
 Hanninen, 2002163 Kuopio Study, Finland 60-76 806 Prevalent NA MCI No effect 
 Busse, 2003188 LEILA 75+, Germany 75+ 1,045 Prevalent NA MCI No effect 
 Ganguli, 2004110 MoVIES, USA 65+ 1,248 Prevalent NA MCI Negative, Men; 1.9, 1.3-2.8 
 Tognoni, 2005184 Vecchiano Study, Italy 65+ 1,600 Prevalent NA MCI No effect 
 Ravaglia, 2008182 CSBA, Italy 65+ 1,016 Prevalent NA MCI No effect 
 Nie, 2010189 Meta-analysis, China 60+ 43,430 Prevalent NA MCI Positive 
 Petersen, 201052 Mayo Study, USA 70-89 1,969 Prevalent NA MCI Negative, Men; 2.31, 1.79–2.99 
 Larrieu, 2002180 PAQUID, France 65+ 2,084 Incident 5 MCI Positive 
 Busse, 2003188 LEILA 75+, Germany 75+ 1,045 Incident 2.6 MCI No effect 
 Solfrizzi, 200450 ILSA, Italy 65-84 2,963 Incident 3.5 MCI No effect 
 Tervo, 200451 CAIDE, Finland 60-76 747 Incident 3 MCI Positive; 1.16, 0.63-2.16 
 Ravaglia, 2008182 CSBA, Italy 65+ 1,016 Incident 4 MCI No effect 
 Luck, 2010178 LEILA 75+ 75+ 1,692 Incident 8 MCI No effect 
 Unverzagt, 201180 ISHA, USA 65+ 1,668 Incident 5 MCI No effect 
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Table 2, Part A (continued). 
Factors Author, year Study, Country Age (yrs) 
Study 
Pop. 
 
Case-
finding 
 
F-up 
(yrs) 
CI 
Def. Association; RR/OR 
Education, low Di Carlo, 200035 ILSA, Italy 65-84 3,425 Prevalent NA CIND Positive, High education; 0.61, 0.56-0.65 
 Frisoni, 200063 KP, Sweden 75+ 1,435 Prevalent NA CIND No effect 
 Unverzagt, 200137 ISHA, USA 65+ 2,212 Prevalent NA CIND Positive 
 De Ronchi, 200539 Faenza Project, Italy 60+ 7,930 Prevalent NA CIND Positive, Illiteracy; 10.9, 7.0–16.7 
 Fei, 200954 Taiyuan Study, China 65+ 6,192 Prevalent NA CIND Positive 
 Gavrila, 200948 Ariadna Study, Spain 65-96 1,074 Prevalent NA CIND No effect 
 Hanninen, 2002163 CAIDE, Finland 60-76 806 Prevalent NA MCI Positive 
 Ganguli, 2004110 MoVIES, USA 65+ 1,248 Prevalent NA MCI Positive; 1.8, 1.2-2.7 
 Solfrizzi, 200450 ILSA, Italy 65-84 2,963 Prevalent NA MCI Negative; 0.04, 0.02-0.07 
 Meguro, 2004183 Tajiri Project, Japan 65+ 1,501 Prevalent NA MCI Positive 
 Tognoni, 2005184 Vecchiano Study, Italy 65+ 1,600 Prevalent NA MCI Positive; High education: 0.66, 0.51-0.85 
 Ravaglia, 2008182 CSBA, Italy 65+ 595 Prevalent NA MCI Positive 
 Nie, 2010189 Meta-analysis, China 60+ 43,430 Prevalent NA MCI Positive 
 Petersen, 201052 Mayo Study, USA 70-89 1,969 Prevalent NA MCI Positive; 2.87, 1.78-4.63 
 Larrieu, 2002180 PAQUID, France 65+ 2,084 Incident 5 MCI Negative 
 Lopez, 200360 CHS, USA 65+ 3,608 Incident 5.8 MCI Positive; High education: 0.8, 0.61-0.99 
 Busse, 2003177 LEILA 75+, Germany 75+ 1,045 Incident 2.6 MCI No effect 
 Solfrizzi, 200450 ILSA, Italy 65-84 2,963 Incident 3.5 MCI Negative; 0.05, 0.03–0.06 
 Tervo, 200451 CAIDE, Finland 60-76 747 Incident 3 MCI Positive, High education: 0.80, 0.71-0.90 
 Ravaglia, 2008182 CSBA, Italy 65+ 1,016 Incident 4 MCI Positive 
 Unverzagt, 201180 ISHA, USA 65+ 1,668 Incident 5 MCI Positive; High education: 0.91, 0.85-0.97 
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Table 2, Part B. Major population-based studies concerning genetic factors and vascular diseases in relation to cognitive impairment no dementia (CIND) and mild 
cognitive impairment (MCI): Odds ratios (OR) or relative risk (RR) with 95% confidence intervals (CIs) are shown. 
Factors Author, year Study, Country Age (yrs) 
Study 
Pop. 
 
Case-
finding 
 
F-up 
(yrs) 
CI 
Def. Association; RR/OR 
APOE-ε4 Sasaki, 200959 Tone Study, Japan 65+ 1,433 Prevalent NA MCI Positive 
 Lopez, 200360 CHS, USA 65+ 3,608 Incident 5.8 MCI Positive; 1.9, 1.14-3.31 
 Tervo, 200451 CAIDE, Finland 60-76 747 Incident 3 MCI Positive; 2.04, 1.15-3.64 
 Monastero, 200751 KP, Sweden 75+ 718 Incident 3.4 CIND No effect 
 Boyle, 201061 RMAP, USA 55+ 600 Incident 10.2 MCI Positive; 1.36, 1.04-1.78 
Stroke Di Carlo, 200035 ILSA, Italy 65-84 3,425 Prevalent NA CIND Positive; 2.05, 1.26-3.35 
 Frisoni, 200063 KP, Sweden 75+ 1,435 Prevalent NA CIND Positive 
 Artero, 200862 3-C Study, France 65+ 6,892 Prevalent NA MCI Positive in men 
 Atti, 201055 Faenza Project, Italy 60+ 7,389 Prevalent NA CIND Positive; 1.91 1.41-2.40 
 Solfrizzi, 200450 ILSA, Italy 65-84 2,963 Incident 3.5 MCI No effect 
 Monastero, 200764 KP, Sweden 75+ 718 Incident 3.4 CIND No effect 
 Luck, 2010178 LEILA 75+ 75+ 1,692 Incident 8 MCI No effect 
Hypertension Kivipelto, 2001185 CAIDE, Finland 65-79 1,449 Prevalent NA MCI No effect 
 Yaffe, 2009190 Osteoporotic Women, Int. 55+ 4,895 Prevalent NA MCI No effect 
 Israeli-Korn, 201065 Wadi Ara Study, Israel 65+ 767 Prevalent NA MCI Positive; 2.08, 1.18-3.65 
 Atti, 201055 Faenza Project, Italy 60+ 7,389 Prevalent NA CIND No effect 
 Solfrizzi, 200450 ILSA, Italy 65-84 2,963 Incident 3.5 MCI No effect 
 Tervo, 200451 CAIDE, Finland 60-76 747 Incident 3 MCI Positive; 1.86, 1.05-3.29 
 Reitz, 200766 MS, USA 65+ 918 Incident 4.7 MCI Positive; 1.40, 1.06-1.77 
 Monastero, 200764 KP, Sweden 75+ 718 Incident 3.4 CIND No effect 
 Luck, 2010178 LEILA 75+ 75+ 1,692 Incident 8 MCI No effect 
Heart Disease Di Carlo, 200035 ILSA, Italy 65-84 3,425 Prevalent NA CIND Positive; 1.73, 1.11-2.68 
 Roberts, 201067 Mayo Study, USA 70-89 1,969 Prevalent NA MCI Positive in na-MCI: 1.93; 1.22-3.06 
 Atti, 201055 Faenza Project, Italy 60+ 7,389 Prevalent NA CIND No effect 
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Table 2, Part B (continued). 
Factors Author, year Study, Country Age (yrs) 
Study 
Pop. 
 
Case finding 
 
F-up 
(yrs) 
CI 
Def. Association; RR/OR 
Heart Disease Solfrizzi, 200450 ILSA, Italy 65-84 2,963 Incident 3.5 MCI No effect 
 Monastero, 200764 KP, Sweden 75+ 718 Incident 3.4 CIND No effect 
 Luck, 2010178 LEILA 75+ 75+ 1,692 Incident 8 MCI No effect 
Diabetes Artero, 200862 3-C Study, France 65+ 6,892 Prevalent NA MCI Positive in men: 1.45, 1.09-1.94 
 Solfrizzi, 200450 ILSA, Italy 65-84 2,963 Incident 3.5 MCI No effect 
 Luchsinger, 2007191 MS, USA 65+ 918 Incident 6.1 MCI Positive; 1.4, 1.1-1.8 
 Roberts, 200868 Mayo Study, USA 70-89 1,969 Prevalent NA MCI Positive in severe cases  
 Luck, 2010178 LEILA 75+ 75+ 1,692 Incident 8 MCI No effect 
 Atti, 201055 Faenza Project, Italy 60+ 7,389 Prevalent NA CIND Positive;  1.53, 1.13-2.08 
 Xu, 2010123 KP, Sweden 75+ 963 Incident 9 MCI/CIND No effect 
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Table 2, Part C. Major population-based studies concerning neuropsychiatric symptoms in relation to cognitive impairment no dementia (CIND) and mild cognitive 
impairment (MCI): Odds ratios (OR) or relative risk (RR) with 95% confidence intervals (CIs) are shown. 
Factors Author, year Study, Country Age (Yrs) 
Study 
Pop. 
 
Case-
finding 
 
F-up 
(yrs) 
CI 
Def. Association; RR/OR 
Depression Kumar, 2006192 Path 60+, Australia 60-64 2,551 Prevalent NA MCI Positive; 1.21, 1.01-1.44 
 Geda, 200883 Mayo Study, USA 70-89 1,969 Prevalent NA MCI Positive; 2.78, 2.06-3.76 
 Artero, 200862 3-C Study, France 65+ 6,892 Prevalent NA MCI Positive; Men: 1.69, 1.27-2.25 
        Positive; Women: 1.26, 1.0-1.6 
 Ravaglia, 2008193 CSBA, Italy 65+ 595 Prevalent NA MCI Positive; 2.1, 1.2-3.9 
 Atti, 201055 Faenza Project, Italy 60+ 7,389 Prevalent NA CIND Positive; 1.75, 1.28-2.39 
 Chan, 201079 HK Study, China 55+ 788 Prevalent NA MCI No effect 
      Lopez, 200360 CHS, USA 65+ 3,608 Incident 5.8 MCI Positive; 1.5, 1.21-1.98 
 Barnes, 200682 CHS, USA  65+ 2,220 Incident 6 MCI Positive, 1.38, 1.03-1.85 
 Monastero, 200764 KP, Sweden 75+ 718 Incident 3.4 CIND Positive; 1.9, 1.1-3.1 
 Panza, 2008134 ILSA, Italy 65-84 2,963 Incident 3.5 MCI No effect 
 Stepaniuk, 2008130 CSHA, Canada 65+ 626 Incident 5 MCI Positive 
 Luck, 2010178 LEILA 75+ 75+ 1,692 Incident 8 MCI No effect 
 Goveas, 201181 WHIMS, USA 65-79 6,376 Incident 8 MCI Positive; 1.98, 1.33-2.94 
 Unverzagt, 201180 ISHA, USA 65+ 1,668 Incident 5 MCI Positive; 2.22, 1.16-4.25 
Anxiety Forsell, 2003194 KP, Sweden 75+ 442 Prevalent NA CIND No effect 
 Kumar, 2006192 Path 60+, Australia 60-64 2,551 Prevalent NA MCI No effect 
 Geda, 200883 Mayo Study, USA 70-89 1,969 Prevalent NA MCI Positive; 3.00, 2.01-4.48 
 Atti, 201055 Faenza Project, Italy 60+ 7,389 Prevalent NA CIND No effect 
 van d. Linde, 201084 MRCCFA Study, GB 65+ 1,781 Prevalent NA MCI/CIND No effect 
 Chan, 201079 HK Study, China 55+ 788 Prevalent NA MCI No effect 
Apathy Geda, 200883 Mayo Study, USA 70-89 1,969 Prevalent NA MCI Positive; 4.53, 3.11-6.69 
 van d. Linde, 201084 MRCCFA Study, GB 65+ 1,781 Prevalent NA MCI/CIND Positive 
 Chan, 201079 HK Study, China 55+ 788 Prevalent NA MCI Positive; 2.06, 1.28-3.30 
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Table 2, Part D. Major population-based studies concerning environmental factors in relation to cognitive impairment no dementia (CIND) and mild cognitive 
impairment (MCI): Odds ratios (OR) or relative risk (RR) with 95% confidence intervals (CIs) are shown. 
Factors Author, year Study, Country Age (Yrs) 
Study 
Pop. 
 
Case-
finding 
 
F-up 
(yrs) 
CI 
Def. Association; RR/OR 
Exercise Geda, 201096 Mayo Study, USA 70-89 1,324 Prevalent NA MCI Negative; mid-life moderate: 0.68, 0.49-0.93 
 Laurin, 200197 CSHA, Canada 65+ 4,615 Incident 5 CIND Negative; 0.58, 0.41-0.83 
 Middleton, 200898 CSHA, Canada 65+ 4,683 Incident 5 CIND Negative in women; 0.62, 0.47-0.84 
Leisure Activities Verghese, 200699 BAS, USA 75-85 437 Incident 5.6 MCI Negative; cognitive: 0.46, 0.24-0.91 
 Monastero, 200764 KP, Sweden 75+ 718 Incident 3.4 CIND No effect 
Social Isolation Artero, 200862 3-C Study, France 65+ 6,892 Prevalent NA MCI Positive in women: 1.21, 1.04-1.42 
 Monastero, 200764 KP, Sweden 75+ 718 Incident 3.4 CIND No effect 
Smoking Di Carlo, 200035 ILSA, Italy 65-84 3,425 Prevalent NA CIND Negative; current: 0.72, 0.54-0.98 
 Atti, 201055 Faenza Project, Italy 60+ 7,389 Prevalent NA CIND No effect; current and past 
 Solfrizzi, 200450 ILSA, Italy 65-84 2,963 Incident 3.5 MCI Positive; frequent vs. infrequent/no smoking 
 Luck, 2010178 LEILA 75+ 75+ 1,692 Incident 8 MCI No effect; lifetime exposure 
Diet Roberts, 201092 Mayo Study, USA 70-89 1,233 Prevalent NA MCI Negative; PUFA: 0.44, 0.29-0.66 
 Roberts, 201091 Mayo Study, USA 70-89 1,233 Prevalent NA MCI Negative; vegetables: 0.66, 0.44-0.99 
 Solfrizzi, 200693 ILSA, Italy 65-84 464 Incident 2.6 MCI No effect; PUFA 
 Eskelinen, 200890 CAIDE, Finland 65-80 1,449 Incident 21 MCI Positive; fat at midlife: 2.36, 1.17-4.74 
 Scarmeas, 200994 MS, USA 65+ 1,875 Incident 4.5 MCI No effect; MeDi Diet 
Alcohol Anttila, 200495 CAIDE, Finland 65-79 1,464 Prevalent 23 MCI Negative; no drinking: 2.08, 1.05-4.13 
        Positive; past hazardous: 2.34,1.15-4.77 
 Espeland, 2005195 WHIMS, USA 65-79 4,461 Incident 4.2 MCI No effect; baseline moderate 
 Atti, 201055 Faenza Project, Italy 60+ 7,389 Prevalent NA CIND Positive; past hazardous: 2.91, 1.05-8.04 
        No effect; current moderate 
 Roberts, 201091 Mayo Study, USA 70-89 1,233 Prevalent NA MCI No effect; current moderate 
 Luck, 2010178 LEILA 75+, Germany 75+ 1,692 Incident 8 MCI No effect; baseline moderate 
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In Table 1, 2 and Figures 1-7: 
YRS = Years 
F-up = Follow-up 
MI = Memory Impairment 
CI = Cognitive Impairment 
Def. = Definition 
OR = Odds Ratio  
RR = Relative Risk 
SD = Standard Deviation; 
Reference = Source of the reference population 
External = An external reference population is used 
Local = The reference is the study population 
NA = Not applicable 
AD = Alzheimer’s Disease 
APOE = Apolipoprotein E gene 
CSHA. Canadian Study of Health and Aging 
KP. Kungsholmen Project 
LEILA 75+. Leipzig Longitudinal Study of the Aged 
MYHAT. Monongahela-Youghiogheny Healthy Aging Team (MYHAT) Project 
Tone Town Study. Study of the town of Tone 
PAQUID. Personnes Agées QUID 
MoVIES. Monongahela Valley Independent Elders Survey 
CSBA. Conselice Study of Brain Ageing 
CAIDE. . The Cardiovascular Risk Factors, Aging and Dementia study 
CHS. Cardiovascular Health Study Cognition Study 
HNRSC. Heinz Nixdorf Recall Study Cohort study 
Mayo Study. The Mayo Clinic Study of Aging 
ILSA. Italian Longitudinal Study on Aging 
ISHA. Indianapolis Study of Health and Aging 
MS. Manhattan Study. 
WHIMS. Women Health Initiative Memory Study 
RMAP. Rush Memory and Aging Project 
3-C Study. Three Cities Study 
Osteoporotic Women Int. International study on postmenopausal women with osteoporosis. 
HK. Hong Kong Study 
MRCCFA. The Medical research Council Cognitive Function and Ageing Study 
BAS. Bronx Aging Study
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2 AIMS 
2.1 GENERAL AIMS 
The general aims of this thesis are to improve our knowledge of the occurrence, 
correlates and risk factors, and progression of cognitive impairment without dementia 
in the elderly population.  
2.2 SPECIFIC AIMS 
The specific aims addressed in four different studies are summarized below. 
1. To determine the prevalence of subjective cognitive impairment and objective 
cognitive impairment in the nondemented elderly population and to explore the 
contribution of genetic background and early life environment to subjective and 
objective cognitive impairment (Study I). 
2. To determine the incidence of cognitive impairment without dementia in the elderly 
population, to examine the impact of attrition due to death on observed incidence 
estimates, and to compare the observed and corrected estimates of the incidence of 
cognitive impairment with incidence rates of dementia (Study II). 
3. To assess the association of common chronic diseases and multimorbidity with 
objective and subjective cognitive impairment without dementia, taking into account 
the contribution of genetic background and early-life environment (Study III). 
4. To investigate the symptom of low mood as a predictor of cognitive impairment and 
its progression to dementia, taking into account cognitive impairment severity, time 
of assessment of low mood symptom, and interaction with other candidate risk 
factors (Study IV). 
Cognitive impairment in the nondemented elderly 
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3 METHODS 
The data used in this thesis are derived from two projects: The Kungsholmen Project 
and The HARMONY Study. 
3.1 THE KUNGSHOLMEN PROJECT (Studies II, and IV)          
3.1.1 Study population                                                                    
The Kungsholmen Project is a community-based cohort study on aging 
and dementia. All registered inhabitants (n=2,368) who were living in the 
Kungsholmen district of Stockholm, Sweden, and were 75 years of age and older on 
October 1st 1987 were initially invited to be part of the project, and 1,810 (76.4%) 
agreed to participate in the baseline survey.196, 197  
Baseline survey. At baseline (1987-1989), a two-phase survey consisting of a 
screening phase and a clinical phase was carried out. The screening phase included a 
health interview and the administration of the MMSE33 for all 1,810 participants. In the 
clinical phase, all subjects who screened positive (MMSE ≤23) and an age - and sex-
stratified random sample of subjects who screened negative (MMSE >23) were invited 
to undertake a comprehensive physical, neurological, and psychiatric assessment, 
similar to the examination usually performed in clinical practice. During the clinical 
phase, 110 subjects refused to participate and 225 persons were diagnosed as having 
dementia according to the Diagnostic and Statistical Manual of Mental Disorders, 
Revised Third Edition criteria (DSM-III-R).6 Thus, 1,475 of 1,810 baseline participants 
were identified as being free of dementia. Of them, 40 subjects had missing data on 
education or MMSE < 20 and were excluded, leaving 1,435 subjects remaining for 
analysis. In Study II, 23 subjects were excluded because of missing data on cognitive 
tests. These values were imputed in Study IV. In addition to this, 342 prevalent cases of 
CI were detected at baseline, in Study II. In Study IV, changes in the way of 
adjudicating years of education led to slight changes in CI classification, which 
identified 337 prevalent cases (5 fewer than in Study II). Therefore, the baseline study 
population comprised 1070 subjects in Study II and then 1098 subjects in Study IV 
(Figure 8). 
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Figure 8. Flowchart of Kungsholmen Project study populations. CI=cognitive impairment. 
Study Participants 
1810 participants (phase I) aged ≥75 years in October 1987 
40 missing education data or MMSE < 20 
1435 dementia-free subjects at baseline survey 
1475 non-demented subjects identified with 2-phase design 
110 refused 
225 prevalent dementias 
Prevalent CI 
342 Study II 
337 Study IV 
Baseline survey 
    1987-1989 
1st follow-up 
1991-1993 
3rd follow-up 
1997-1998 
2nd follow-up 
1994-1996 
Time Period 
23 missing data on tests 
(Study IV: data imputed) 
Dementia and CI-free with complete data at baseline 
1070 Study II 
1098 Study IV 
Dementia and CI-free at first follow-up 
742 Study II 
764 Study IV 
Deceased 
195 Study II 
199 Study IV 
Drop-outs 
133 Study II 
135 Study IV 
 
Dementia and CI-free at second follow-up 
400 Study II 
424 Study IV 
Deceased 
112 Study II 
116 Study IV 
Drop-outs 
30 Study II 
34 Study IV 
 
Incident dementia/CI 
200 Study II 
190 Study IV 
Dementia and CI-free at third follow-up 
204 Study II 
216 Study IV 
Deceased 
57 Study II 
62 Study IV 
Drop-outs 
16 Study II 
18 Study IV 
 
Incident dementia/CI 
123 Study II 
128 Study IV 
Dementia and CI free 
154 Study II 
161 Study IV 
Dementia/CI 
50 Study II 
55 Study IV 
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Follow-up examinations. After the baseline survey, study participants underwent four 
waves of follow-up examinations, each with an average three-year interval.198 In both 
Study 2 and Study 4, the first three waves of follow-up examinations were used (Figure 
8). At each follow-up, all surviving subjects were assessed by way of a structured 
interview carried out by nurses and a clinical examination performed by physicians, 
which included basic cognitive testing. When possible, additional neuropsychological 
tests were performed by psychologists. If the subject was not able to answer, an 
informant, usually a next-of-kin, was interviewed. For those subjects who had died 
before the follow-up examination, information regarding their health status was 
obtained from the computerized inpatient register system, which is a register of 
discharge diagnoses from all Stockholm hospitals since 1969. The individual hospital 
records, discharge diagnoses, and death certificates were examined. 
3.1.2 Data collection 
During the screening phase of the baseline survey, a health interview was carried out to 
collect data on demographics, medical history, and cognitive functioning. The clinical 
phase of the baseline survey consisted of a dementia work-up including a structured 
interview, a comprehensive clinical examination, and psychological tests implemented 
following the standardized protocols.196-198 
3.1.2.1 Demographics 
Data on demographic variables (e.g., age, sex, and education) were collected from the 
subjects at the baseline interview. Years of education were derived by summing up the 
duration in years of the different levels of formal schooling (according to the Swedish 
system). The variable was dichotomized into low (<8 years) vs. high ( ≥8 years) 
according to a previous study within the Kungsholmen Project.53 When adjudicating 
years of formal education, professional training was first counted as formal schooling 
but was later reclassified as non formal, extra curriculum, education. 
3.1.2.2 Medical history 
Data on medical history or comorbidities at baseline and during the entire follow-up 
period were obtained from the computerized inpatient register system, which recorded 
up to six different diagnosed disorders during each hospital admission. The 
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International Classification of Disease, Eight Revision (ICD-8) was used by the register 
system until 1986. Since 1987 the ICD Ninth Revision (ICD-9) has been employed.  
3.1.2.3 Medical drug use 
Data on medical drug use for the two weeks prior to the baseline interview were 
collected from the subjects and verified by inspecting drug prescriptions and containers. 
Medical drugs were coded in accordance with the Anatomical Therapeutic and 
Chemical (ATC) classification system.199 Antidiabetic drugs were considered as 
medications used to control blood glucose levels (hypoglycemic medications or insulin 
injection, ATC code A10). Antihypertensive drugs were defined as all medicines 
potentially used for lowering blood pressure (ATC codes C02, C03, and C07).  
3.1.2.4 Clinical and genetic information 
Weight and height were measured using a standard scale in light clothing and no 
shoes.200 BMI was calculated as weight in kilograms divided by squared height in 
meters. Arterial blood pressure (i.e., systolic Korotkoff phase I and diastolic phase V) 
was measured by nurses with the subjects seated after at least a five minute rest. Blood 
samples were taken at baseline and at each follow-up examination. Blood glucose level 
was measured using a glucose oxidase procedure.201 Data on blood glucose were 
available for 95.9% (n=1,248) of the dementia-free subjects at baseline. Genomic DNA 
was prepared from peripheral blood samples that were taken at baseline, and APOE 
allelic status was determined following a standard procedure.202  
3.1.2.5 Psychiatric evaluation 
At baseline, nurses assessed mental health as part of a general health status interview 
consisting of questions with yes/no answers. The questionnaire investigated different 
health-related symptoms and included items on depressive symptoms, such as low 
mood, anxiety, feelings of loneliness, sleeping disturbances, reduced appetite, and 
tiredness. All of these symptoms aside from loss of appetite loaded on the same factor, 
as shown by a factor analysis with varimax rotation performed at baseline. Low mood 
had the highest loadings on this depression factor (0.81), followed by feelings of 
loneliness (0.70) and anxiety (0.64). At follow-ups, all patients underwent a structured 
psychiatric interview performed by physicians and based on the Comprehensive 
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Psychopathological Rating Scale (CPRS).203 The interview covered several 
psychopathological areas, comprising symptoms of depression and anxiety. Mood-
related symptoms included: low mood, suicidal ideation/thoughts of death, feelings of 
guilt and appetite disturbances. For each symptom, scores were graded in degrees of 
severity on a scale from 0 (the absence of a symptom) to 6 (extreme severity of the 
symptom). Scores were dichotomized into yes, for all scores exceeding 0, versus no, 
for a score equal to 0 (Study IV). 
3.1.2.6 Cognitive assessment 
Nurse interview. At baseline and follow-ups nurses collected subjective memory 
complaints by asking whether the participants had experienced troublesome memory 
problems recently. Functioning in daily life was investigated with the Katz Index of 
Activities of Daily Living (Katz’ ADL).204 All subjects were also evaluated with the 
Mini Mental State Examination (MMSE),33 a measure of global cognitive functioning 
which encompasses basic cognitive functions, such as orientation, language, attention, 
episodic memory, and visuospatial abilities. The MMSE’s score ranges from a 
minimum of 0 (worse performance) to a maximum of 30 (best performance). The 
MMSE is the most extensively studied screening tool for dementia. A meta-analysis of 
34 studies separated into high and low prevalence settings reported optimal 
psychometric properties for the MMSE.205 In memory clinic settings the MMSE had a 
pooled sensitivity (Se) of 79.8%, a specificity (Sp) of 81.3%, a positive predictive value 
(PPV) of 86.3% and a negative predictive value (NPV) of 73.0%. In mixed specialist 
hospital settings the Se, Sp, PPV and NPV were 71.1%, 95.6%, 94.2% and 76.4%, 
respectively. In non-clinical community settings the MMSE had a pooled Se of 85.1%, 
a Sp of 85.5%, a PPV of 34.5% and an NPV of 98.5%. In those studies conducted 
purely in primary care the Se, Sp, PPV and NPV were 78.4%, 87.8%, 53.6% and 
95.7%, respectively. Thus the case-finding ability of the MMSE was best when 
confirming a suspected diagnosis in specialist settings with correct identification made 
in 27/30 positive results. It was modestly effective at ruling-out dementia in specialist 
settings. Conversely, in non-specialist settings, the MMSE was best at ruling out 
dementia, achieving about 29/30 correct classifications with less than three false 
negatives out of every 100 screens. Recently, the MMSE has also been found to be a 
promising screening tool for non-dementia CI.206 A MMSE score of < or =28 showed a 
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sensitivity of 85.5% and a specificity of 66.7% for MCI compared with a definition 
based on a 60-min battery of validated tests evaluating different cognitive domains.206  
In all cases suspected of CI, an interview with a next-of-kin was also conducted by 
nurses, to evaluate if there had been any significant change in cognitive abilities and 
whether the cognitive impairment was interfering with daily life activities. The 
interview was based on the Section H of the CAMDEX.138 
Physician interview. At baseline and follow-ups physicians performed a cognitive 
examination covering: i) autobiographic and semantic memory, investigated by asking 
facts of general knowledge and past personal information; ii) language, investigated by 
object naming and speech comprehension; iii) abstract thinking, investigated with 
problem solving simulation and proverbs; and iv) visuospatial abilities and praxis, 
investigated by repeating simple motor activities and by copying figures.196 From the 
first follow-up onwards, episodic memory, measured with the word recall task207 
described below, and attention/working memory, measured with the digit span forward 
and backwards,208 were also included in the standard dementia workup. The word 
recall task consists of reading aloud a set of 12 commonly used words to the subject 
who is asked to remember as many words as possible. After the words presentation, to 
be carried out at a pace of 2 seconds per word, the subject says all the words she can 
recall, aloud and in a random order. The score, which ranges from a minimum of 0 
(worst performance) to a maximum of 12 (best performance), represents the total 
number of correct hits. The test has been validated within the Kungsholmen Project.207  
Additional neuropsychological tests. A sub-sample of participants received further 
neuropsychological assessment performed by psychologists. The evaluation included 
tests covering different cognitive domains. Attention and executive functions were 
tapped by the Trail Making test;209 episodic memory was examined with tests of free 
and organized recall of random words plus a recognition task,207 and with a test of face 
recognition;207 visuospatial abilities were tapped with the block design task from the 
WAIS,208 and the clock reading test;210 verbal abilities were examined with letter and 
category fluency tasks.211 
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3.1.3 Diagnosis of dementia 
The clinical diagnosis was based on 1) the next-of-kin interview performed by nurses, 
as described above;138 and 2) a clinical examination performed by two physicians. The 
clinical examination was similar to a comprehensive geriatric examination usually 
performed in a clinical practice, but structured and defined with scoring criteria. It 
included a medical history, a physical and neurological examination, a cognitive 
examination (as described above), and assessment of depression (mood-related section 
of the CPRS).203 DSM-III-R diagnostic criteria6 were used for the clinical diagnosis of 
dementia and different types of dementia. Moreover, when only one item in the 
diagnostic criteria was not fulfilled, the subject was classified as affected by 
questionable dementia.  The diagnostic procedure, which has been validated, comprised 
three steps.196-198 In step one, a preliminary diagnosis was made after a common 
discussion among the physicians who examined the patient and the nurses who 
performed the next-of-kin interview. In step two, an external physician blind to the 
preliminary diagnosis made a second diagnosis based on collected data. In step three, in 
cases of discrepancy between the two diagnoses, a senior physician was consulted to 
make the final diagnosis. 
The differential diagnosis of AD required gradual onset, progressive deterioration, and 
the lack of any other specific causes of dementia. The diagnosis of VaD required abrupt 
onset, stepwise deterioration, history of stroke, or focal deficits. Hachinski’s ischemic 
scale212 was used to support the differential diagnosis between AD and VaD. The 
diagnostic criteria used for AD and VaD were equivalent to “probable AD” according 
to the National Institute of Neurological and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria213 
and to “possible VaD” according to the NINDS-AIREN criteria,212 respectively.  
For subjects who died in between follow-up examinations, two physicians made a 
diagnosis of dementia or subtypes by thoroughly reviewing medical records and death 
certificates.198 
3.1.4 Definition of cognitive impairment 
In people that were dementia-free according to the clinical examination, syndromes of 
cognitive impairment were defined using both MCI and CIND criteria. 
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3.1.4.1 MCI 
MCI was defined according to the original Mayo Clinic criteria for aMCI and was 
operationalized as follows: 1) Memory complaint was defined as a report by the 
subject, the next-of-kin, or both; 2) Normal general cognitive function was defined as 
scoring above a previously defined cutoff for cognitive impairment of 1 SD below 
age and education-specific means on the MMSE; 3) Absence of dementia was 
determined by physicians as described above; 4) Normal activities of daily living was 
defined as the absence of functional impairment on Katz’ ADL scale, or slight 
functional impairment which was judged by the examining physician not to be 
attributable to cognitive impairment; 5) Objective memory impairment was defined as 
scoring at least 1.5 SD below age- and education-specific means on the word recall 
task described above. The means were based on age quartiles of the population at first 
follow-up, stratified by level of education (high vs. low). At baseline, prevalent cases 
of aMCI were defined as scoring 1.5 SD below the mean performance of the 
dementia-free population on the episodic memory section of the MMSE, 
corresponding to complete failure in recalling the three items. The cut-off of 1.5 SD, 
chosen both at baseline and follow-ups, has been shown to have increased stability 
over time compared to less stringent cut-offs, and minimizes the “back-to-normal” 
effect often observed in MCI when using a single test of episodic memory.214  
3.1.4.2 CIND 
CIND was defined as global cognitive impairment and operationalized as follows: 1) 
Absence of dementia was determined by physicians as described above; 2) Objective 
global cognitive impairment was defined as scoring at least 1 SD below age- and 
education-specific means on the MMSE. The means were based on seven age strata 
of the dementia-free population at baseline stratified by education (high vs. low).  The 
cutoff of 1 SD was chosen in order to include cases with even slight global cognitive 
impairment. The term oCIND, previously used in the PAQUID study with a similar 
meaning,180 was preferred to the term CIND in order to avoid confusion with the 
different definition adopted by the Canadian and Indianapolis studies36, 37, 46 as well as 
emphasizing the inclusion of non-dementia cognitive impairment cases other than 
aMCI. 
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Because of the adopted criteria, aMCI and oCIND were mutually exclusive. This 
allowed the definition of a larger group of cognitively impaired subjects without 
dementia, which included both aMCI and oCIND cases. 
3.1.5 Covariates 
Education was dichotomized into less than 8 years (low education) and more than 7 
years (high education). 
Age was categorized into four groups: 75-79, 80-84, 85-89, 90+ (Study II) and 
dichotomized based on the median of the population at each wave (Study IV). 
Depressive symptoms (Study II) included reported perceived sadness and feelings of 
loneliness, from the general health interview performed by nurses at baseline. For the 
variable low mood, which was the main exposure in Study IV, information on 
perceived sadness from the baseline general health status interview and from the CPRS 
performed at follow-ups was merged. 
Dissatisfaction with own health was coded based on responding with a “no” to the 
question “Do you feel healthy?”, which was part of the general health interview at 
baseline (Study II). 
Several diagnoses derived from the Inpatient Register were used in both Study II and 
IV: hip fracture in the last year (ICD-8 and ICD-9 codes 820, 821), history of 
cerebrovascular disease (ICD-8 and ICD-9 codes 430-438), history of heart failure 
and arrhythmia (ICD-8 and ICD-9 codes 427-429), history of psychosis (ICD-8 and 
ICD-9 codes 291-298). 
For diabetes, information from the Inpatient Register (ICD-8 and ICD-9 code 250) 
was integrated with information from two additional sources: using blood glucose-
lowering medications (ATC code A10), or having blood glucose (nonfasting) level 
higher than 11 mmol/L. Multimorbidity was defined as having two or more chronic 
diseases, based on diagnoses from the Inpatient Register (Study IV). 
In Study II, further variables derived from the Inpatient Register were: operation 
within the last six months (any surgical intervention during a hospital admission in 
the previous six months), hospitalization within the last six months (any hospital 
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admission or discharge in the previous six months), malignancy and unspecified 
tumors in the last year (ICD-8 and ICD-9 codes 140-209, 230-239). 
Variables regarding the use of medications were: polypharmacy, the absolute number 
of drugs used, as collected by a nurse and coded as a three-level ordinal variable: no 
drug use, one-to-four drugs, or five or more drugs; antihypertensive drugs use (ATC 
codes C02, C03, C07, C08 and C09) (Study II). In Study IV, psychoactive drugs were 
coded as follows: neuroleptics (ATC code: N05A), anxiolytics (ATC code: N05B), 
hypnotics and sedatives (ATC code: N05C), and antidepressants (ATC code: N06A). 
High blood pressure was defined as ≥ 180 a rterial blood pressure (i.e., systolic 
Korotkoff phase I and diastolic phase V) (Study IV). 
Social network was used as an indicator of social integration and coded as a four-level 
ordinal variable (extensive/moderate/limited/poor social network, based on 
information collected by nurses). ApoE-ε4 allele was the only genetic factor 
considered, and was dichotomized into being a carrier of one or two ε4 alleles versus 
carrying no ε4 allele. 
3.2 THE HARMONY STUDY (Studies I and III) 
3.2.1 Study population 
Participants were members of the population-based Swedish Twin 
Registry that was established in the 1960s, when all the twins in 
Sweden were identified.215 In 1998-2001, all living twins in the 
registry, both same- and unlike-sex, who were born in 1935 and earlier (aged ≥65 
years) were invited to participate in a study concerning dementia known as 
HARMONY, which is taken from the Swedish words for “health” (Hälsa), “genes” 
(ARv), “environment” (Miljö), “and” (Och), and “new” (NY).216 Of the 20,269 eligible 
twin individuals, 5,771 could not be contacted by phone and 712 were contacted but 
were unable to partake in the interview and there was no available informant. For a 
further 93 subjects the information was incomplete or missing. Of the remaining 
13,693 twin individuals, 1,138 were not available for interview because of sickness or 
severe cognitive impairment but there was an interviewable next of kin. 
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A total of 1,939 individuals were invited to participate in the clinical phase, including: 
1) all twins who were screened positive; 2) those who were not able to be screened by 
telephone if the informant gave an indication that the reason was dementia; 3) twin 
partners to those who were diagnosed with dementia; and 4) normal controls. Clinical 
diagnoses were available for 1,357 individuals. 
Finally, out of the 12,555 participants with cognitive screening data we excluded 
people with: clinical diagnosis of dementia (n=144), questionable dementia (n=125), 
cognitive impairment but missing clinical workup (n=358), and mental retardation 
(n=1). The final cohort consisted of 11,927 dementia-free twin individuals available 
for analysis in Study I (Figure 9). Out of this sample, 548 subjects were further 
excluded because of missing data on covariates, leaving 11,379 twin individuals 
available for Study III (Figure 9). 
The participation rates were 71.4% for the screening phase, and 70.0 % for the clinical 
phase. The prevalence of dementia in this Swedish twin cohort was comparable with 
several major epidemiological studies of dementia prevalence in Europe and the 
USA.216 
3.2.2 Data collection 
The screening phase of HARMONY was performed telephonically and consisted of 
two parts. A general health interview, which focused on sociodemographic aspects and 
zygosity, health status, affective symptoms, and common diseases. During the general 
health interview subjects were asked if they agreed to participate in a cognitive 
evaluation, executed over the telephone, and covering different aspects related to 
subjective and objective cognitive functioning and activities of daily living. 
Further information on medical diseases was derived from the inpatient registry system. 
The ICD-8 was used by the register system until 1986. The 9th revision (ICD-9) was 
used since 1987 onwards. 
3.2.3 Cognitive evaluation 
The cognitive evaluation consisted of the previously validated telephonic interview 
(TELE).217, 218 Performance  on  the  TELE is  summarized  in  a  total  score that ranges  
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Figure 9. Flowchart of HARMONY study populations. 
from 0 (worst performance) to 19 (best performance). TELE examines the following 
four cognitive areas: 1) orientation, assessed by 10 items of the mental status 
questionnaire (MSQ);219 2) attention, measured by counting backwards in threes;220 3) 
reasoning, tapped with questions about similarities and differences between pairs of 
nouns;221 and 4) episodic memory, evaluated using a three-item free recall task.33 In 
case of failure to recall all the items in the free recall condition, the subjects were 
administered a recognition task, in which they were required to identify the correct 
word or words within a list of distractors. TELE includes also a section investigating 
cognitive complaints, with a general question ascertaining subjective cognitive change 
“Have you noticed any change in your memory during the last three years?”, followed 
20,269
Eligible twins aged ≥ 65
14,498
Reached by phone
5771 Dropouts
13,693
Screened
712 Not interviewable and no informant report
93 Incomplete or missing data
12,555
With TELE
1138 Not interviewable but informant report
11,927
Nondemented twins
358 Cognitively impaired, no clinical workup
269 Definite or questionable dementia
1 Mental retardation
Clinical
Study I
11,379
Nondemented twins with 
complete data
548 Missing data on covariates
Study III
Workup
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by more specific questions focusing on different cognitive problems such as forgetting 
errands, forgetting people’s names, forgetting appointments, forgetting known places, 
and forgetting words. Further questions addressed whether respondents were living 
independently, their employment status, their recent visits for medical care, their 
eyesight and hearing, assistance with practical tasks in daily life, and their mood. 
When people did not perform optimally or could not perform TELE, an informant was 
interviewed with questions regarding the subject's health, functional status, activities of 
daily living, and employment status. If cognitive problems were indicated, follow-up 
questions were used to obtain a history of the impairment and the pattern of decline, as 
well as a description of any contacts with the healthcare system concerning health 
problems. The eleven items of the Blessed Dementia Rating Scale (BDRS) were also 
included in the informant interview to assess cognitive functioning in everyday 
activities. The BDRS ranges from 0 to 17, with higher score indicating greater 
frequency of problems.222 
Finally, people who were suspected of cognitive dysfunction according to TELE and 
BDRS combined underwent a comprehensive dementia workup. The dementia workup 
included a physical and neurological examination, a review of medical history, an 
informant interview, and a neuropsychological assessment as described in the protocol 
of the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). 
3.2.4 Diagnosis of dementia 
Clinical diagnoses of dementia followed Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV) criteria.7 Preliminary diagnoses made by the 
interviewing team were reviewed by a diagnostic board consisting of a neurologist and 
a psychologist. When DSM-IV criteria were completely fulfilled, subjects were 
diagnosed as having “dementia” in contrast with a category of “questionable 
dementia”, which was used for individuals who did not fulfill one of the first three 
DSM-IV diagnostic criteria but did exhibit either cognitive impairment or functional 
disability.223 
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3.2.5 Definition of subjective and objective cognitive impairment 
3.2.5.1 SCI 
SCI was defined as any perceived cognitive change in the last three years in otherwise 
cognitively intact people. The operationalization criteria of SCI included: 1) presence 
of subjective cognitive complaints defined as self-reported memory change within the 
last three years when the subject was questioned as part of TELE; 2) absence of 
objective cognitive impairment defined as CIND, as described below; 3) absence of 
dementia defined on the basis of the clinical diagnosis, as described above. 
3.2.5.2 CIND 
CIND was defined as any cognitive impairment in the absence of dementia,36, 37, 46 
using the following operationalization criteria: 1) presence of cognitive impairment 
defined as a performance at least two standard deviations below the age and education 
specific mean in any of the four cognitive TELE tasks; and 2) absence of dementia 
defined on the basis of a clinical diagnosis following the DSM-IV criteria, as described 
above. The age-and education-specific means of TELE’s cognitive tasks were based on 
the average performance of the dementia-free population classified into eight age- and 
education-specific groups. A conservative cut-off of 2 SD below the mean was chosen 
to improve specificity in the face of relatively simple cognitive tests. 
Due to the operational definition adopted in this study, SCI and CIND were mutually 
exclusive. 
3.2.6 Covariates 
3.2.6.1 Sociodemographics and zygosity 
Information on age and sex was obtained from the Swedish Twin Registry. Information 
on education and zygosity was gathered during the subject’s telephonic interview and 
verified by an informant when the subject was unable to be interviewed or did not 
perform well on the TELE. The validity of ascertainment of zygosity based on a 
telephonic interview has been tested against blood markers and found valid in 99% of 
the cases.224 
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Age in years was categorized into four groups of five years each, plus a fifth group of 
people over 85 years of age. 
Education was categorized into three groups based on the years of attained formal 
education, ranging from low (0 to 7 years), to average (8 to 10 years) and high (more 
than 10 years) education. 
Information on marital status was dichotomized into married versus non married, 
including in the married category couples who were cohabiting without being married. 
Occupation was defined on the basis of an open question about the subject’s main 
occupation in life. These were assigned occupational codes by Statistics Sweden and 
those codes were categorized as either h
225
igh occupational SES, including all “white 
collars” when the main occupation was non-manual, or low occupational SES, 
including all “blue collars” when the main occupation in life was manual.  
There were four possible categories of the variable zygosity: monozygotic, in the case 
of identical twins; same-sex dizygotic; unlike-sex dizygotic; and undetermined. This 
latter category included twin individuals for whom zygosity could not be ascertained. 
3.2.6.2 Chronic diseases 
Medical history was ascertained based on information coming from two sources: a) the 
Inpatient Register system, and b) self- and informant reports. The inpatient register 
encompasses all hospital’s admissions in Sweden from 1969 onwards. The 
International Classification of Disease, 8th revision (ICD-8) was used in the register 
system until 1986; from 1987 onwards the International Classification of Disease, 9th 
revision (ICD-9) was used. 
Diagnoses regarding common chronic diseases226 were grouped according to the 
International Classification of Disease, 9th revision (ICD-9) as described in Table 3. 
More specifically, psychosis (dementia excluded) and affective disorders included ICD-
8, 9 codes: 291-299. Ischemic heart disease included ICD-8, 9 codes: 410-414. Cardiac 
dysrhythmia, heart failure or other myocardial insufficiency included ICD-8, 9 codes: 
427 and 428. Hypertension included ICD-8 codes: 400-404; and ICD-9 codes: 401-405. 
Stroke included ICD-8, 9 codes: 430-438. Articular diseases included ICD-8 codes: 
712-718; and ICD-9 codes: 710-719. Osteoporosis included ICD-8 code: 723; and 
ICD-9 code: 733.  Hip  fracture  included  ICD-8  code:  N820;  and  ICD-9  code: 821. 
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Table 3. Chronic diseases clusters according to ICD-9 (WHO). 
Disease groups  Diseases in the group 
Mental  Psychosis and affective disorders 
Circulatory  Ischemic heart disease, cardiac dysrhythmia, heart 
failure or other myocardial insufficiency, hypertension, 
stroke 
Musculoskeletal  Articular diseases, osteoporosis, hip fracture 
Respiratory  Chronic obstructive pulmonary disease, emphysema, 
asthma 
Endocrine  Diabetes, thyroid dysfunction 
Gastrointestinal  Intestinal diverticula, ulcerous colitis, Chron’s disease, 
liver cirrhosis, cholelithiasis 
Urological  Renal failure, renal calculosis, prostate hypertrophy, 
recurrent cystitis 
Malignancy  Malignant tumors 
Chronic obstructive pulmonary disease (COPD) included ICD-8, 9 code: 491. 
Emphysema included ICD-8, 9 code: 492. Asthma included ICD-8, 9 code: 493. 
Diabetes included ICD-8, 9 code: 250. Thyroid dysfunction included ICD-8, 9 codes: 
240-246. Intestinal diverticula included ICD-8, 9 code: 562. Ulcerous colitis included 
ICD-8 code: 563, and ICD-9 code: 556. Crohn’s disease included ICD-8 code: 563; 
and ICD-9 code 555. Liver cirrhosis included ICD-8, 9 code: 571. Cholelithiasis 
included ICD-8, 9 code: 574. Renal failure included ICD-8 code: 582; and ICD-9 code 
585. Renal calculosis included ICD-8, 9 code: 592. Prostate hypertrophy included 
ICD-8, 9 code: 600. Recurrent cystitis included ICD-8, 9 code: 595. Malignant tumors 
included ICD-8 codes 140-209; and ICD-9 codes: 140-208. 
According to previous research, multimorbidity was defined as having at least two 
chronic diseases co-occurring in the same individual.226 
3.2.6.3 Current affective symptoms 
Depressive symptoms were assessed during the telephone screening using the short 
form of the Center for Epidemiologic Studies Depression Scale (CES-D).227, 228 The 
short CES-D consists of 11 items scored on a 0 to 4 scale and related to the frequency 
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of symptoms (from 0=rarely/none to 4=Most/All of the time). Two items referring to 
feeling happy and enjoying life are reverse scored. The other nine items refer to poor 
appetite, feeling depressed, feeling like everything is an effort, restless sleep, feeling 
lonely, feeling that people are unfriendly, feeling sad, feeling disliked, and the feeling 
of not being able to “get going”. CES-D total score was dichotomized using a cut-off of 
9.229 
Anxiety symptoms were assessed during the telephone screening by using the 
Composite International Diagnostic Interview – Short Form (CIDI-SF).230 People were 
classified as having current anxiety symptoms if they reported any episode of worry or 
anxiety and answered positively to the question “are you still anxious?”. 
3.3 ANALYTICAL AND STATISTICAL STRATEGIES 
The main aims of this thesis were achieved by carrying out a set of different analytic 
strategies, which implied the use of a wide range of statistical techniques. A summary 
of the analytical and statistical strategies used in each study is shown in Table 4. 
3.3.1 General analytical strategies 
1. Occurrence of CI. The occurrence of non-dementia CI was estimated both 
cross-sectionally (Study I) and longitudinally (Study II). Incidence rates were 
estimated using 9-year follow-up data and were corrected for the possible bias 
caused by attrition due to death. 
2. Correlates and risk factors for CI. Different correlates and risk factors for 
non-dementia CI were investigated. The effect of age and gender on CI 
frequencies was evaluated both cross-sectionally (Study I) and longitudinally 
(Study II). Other sociodemographic characteristics such as education, marital 
status, and occupational SES were evaluated on prevalent CI cases (Study I). 
The contribution of familial factors, such as genetic background and early life 
environment, to CI syndromes was evaluated using prevalent cases (Study I). 
Association with history of chronic diseases and multimorbidity was evaluated 
on prevalent cases of non-dementia CI, taking into account the role of familial 
factors (Study III). Finally, low mood was investigated as a possible risk factor 
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for non-dementia CI, using 6-year follow-up data to estimate a 3-year risk and 
taking into account also other candidate risk factors for CI (Study IV). 
3. Progression to dementia. Low mood was the only factor studied in relation to 
the progression of CI to dementia (Study IV) and was studied using 6-year 
follow-up data to estimate a 3-year progression risk. 
3.3.2 General statistical procedures 
Throughout the four studies a range of statistical tests was employed. However, the 
following techniques were used in all studies. 
1) Chi-square test and Student’s t-test or analysis of variance were performed to assess 
the statistical differences of proportions and means between groups. The Mann-
Whitney test was used to test for differences in the medians between groups for 
continuous variables with non-normal distribution. 
2) Missing information was estimated using Multiple Imputation, which assigns a 
value of 0 or 1 to the missing values. The procedure consists of three steps: firstly, 
all the variables that are considered related to the variable of interest are used as 
predictors to generated multiple plausible estimates of the missing values, which 
are stored in different datasets; secondly, independent data analyses are carried out 
on each complete dataset; finally, the different estimates are pooled together 
according to Rubin’s formula.231 
3) The combined effect of two factors was assessed by creating dummy variables 
based on the joint exposures to both factors. The statistical interactions were 
examined by incorporating the independent variables and cross-product terms in the 
same models. 
All data analyses were carried out using SPSS statistical package (versions 14.0-18.0 of 
PASW for Windows, SPSS Inc., Chicago, IL, USA) and Stata (versions 9.0-10.0 for  
Windows, Stata-Corp, College Station, Texas). 
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3.3.3 Specific statistical procedures 
3.3.3.1 Study I 
1) Prevalence rates (cases per 100 subjects) were calculated in five different age 
groups according to sex and education. Ninety-five percent confidence intervals 
(95% CI) were calculated based on the binomial distribution. 
2) Probandwise Concordance was calculated according to the formula of 
2C/(2C+D), in which C is the number of twin pairs concordant for the studied 
outcome and D is the number of discordant twin pairs.232 
3) Tetrachoric Correlations with 95% confidence intervals were run to further 
investigate the conditional probability of a twin to be affected by the outcome of 
interest, given that the co-twin was affected. Tetrachoric correlations represent the 
correlation of liability between relatives and are analogous to intra-class 
correlation based on continuous data.232 
Both probandwise concordance and tetrachoric correlations were performed for 
monozygotic, dizygotic same-sex and dizygotic unlike-sex twin pairs independently. 
3.3.3.2 Study II 
1) Incidence rates were calculated as the number of new events divided by the time at 
risk (person-years), with 95% confidence intervals (CI) calculated according to the 
Poisson distribution. Subjects were considered at risk of developing dementia until 
they either 1) received a diagnosis of dementia; 2) dropped out from the study due 
to refusal or moving; or 3) died. Subjects were considered at risk of developing 
non-dementia CI until they either 1) received a diagnosis of dementia; 2) were 
classified for the first time as affected by a CI syndrome; 3) dropped out of the 
study due to refusal or moving; or 4) died.  
2) Poisson Regression was used to evaluate the relative risk (RR) of having cognitive 
impairment associated with sociodemographic factors. 
3.3.3.3 Studies I and III 
Association of subjective and objective cognitive impairment with the covariates of 
interest was carried out following two strategies: 
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1) Unmatched generalized estimating equations (GEE) models on the whole cohort, 
which are conceptually equivalent to logistic regression but controls for the 
clustering of twins within a pair; 
2) Conditional Logistic Regression on the twin pairs discordant for cognitive status, 
which allows matching for unmeasured familial factors, such as genetic background 
and early life environment.  
If the association found with GEE models becomes attenuated in Conditional Logistic 
Regression models, familial factors are likely to play a role in the association. In 
contrast, if the association remains significant, the influence of genetic background and 
early environmental factors are likely to be marginal.224 
3.3.3.4 Study IV 
1) Multiple Cox Proportional-Hazards models were used to estimate the relative risk 
and 95% CI of syndromes of CI and dementia associated with baseline low mood, 
taking into account several potential confounders. For cases detected at the first 
wave of examinations, the baseline for low mood exposure was set at the study 
baseline. For cases detected at second wave of examinations, the baseline for low 
mood exposure was set at the second wave (first follow-up). The relative risks of CI 
in relation to baseline low mood were comparable between the two waves, 
therefore Cox regression analysis was performed using data from both waves. In 
order to preserve the three-year follow-up exposure for CI, baseline LM and all 
other variables varying with time were entered as time-dependent variables. 
2) The same strategy was used in people with incident non-dementia CI to estimate 
the relative risk of progressing to dementia in relation to baseline low mood. 
3) To test for additive interaction, the attributable proportion (AP) due to interaction 
was calculated together with the 95% CI.233  
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Table 4. Summary of the analytical and statistical strategies used in each study. 
Study Aims Main Covariates Outcomes Other Covariates Main statistical procedures 
      
Study I Prevalence; age-, gender-, 
and education-specific 
prevalence; association with 
sociodemographic factors; 
effect of familial factors  
Age; gender; education; 
familial factors 
SCI and CIND Marital status; occupational SES Prevalence proportions; 
Generalized Estimating Equations; 
Conditional Logistic Regression; 
Concordance rates; 
Tetrachoric correlations 
      
Study II Incidence; age- and gender-
specific incidence; 
association with 
sociodemographic factors; 
correction for attrition 
Age and gender aMCI and oCIND Education; dissatisfaction with own health; 
hip fracture; operation; hospitalization; 
malignancy; number of drugs; stroke; heart 
disease; antihypertensive drugs use; 
diabetes; psychosis; depressive symptoms; 
social network; Apoe-ε4 
Incidence density; 
Poisson Regression; 
Multiple Imputation 
      
Study III Association with chronic 
diseases; association with 
multimorbidity; effect of 
familial factors 
Chronic diseases; 
multimorbidity; familial 
factors 
SCI and CIND Age; gender; education; affective symptoms Generalized Estimating Equations; 
Conditional Logistic Regression 
      
Study IV Association with low mood 
(CI development and 
progression) 
Low mood aMCI and oCIND Age; gender; education; history of 
psychosis; psychotropic drug use; ApoE-ε4 
allele; history of cerebrovascular disease; 
heart disease; diabetes; high blood 
pressure; hip fracture; multimorbidity; 
polypharmacy; social network 
Cox Proportional Hazards 
Regression; Attributable Proportion 
SCI: subjective cognitive impairment; CIND: cognitive impairment no dementia; aMCI: amnestic mild cognitive impairment; oCIND other cognitive impairment no 
dementia; CI: cognitive impairment.
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4 ETHICAL CONSIDERATIONS 
4.1 THE KUNGSHOLMEN PROJECT 
All people living in the Kungsholmen district aged ≥75 years and eligible for the study 
at baseline were sent a personal letter explaining the nature of the project and the 
importance of the subject’s participation, yet emphasizing that this was voluntary. 
Thereafter, all participants were contacted by phone to check their availabilities, and to 
book a date for their first visit. At the screening evaluation, informed consents were 
obtained directly from the subject, after explaining the aims of the project and 
clarifying that all information would be kept strictly confidential. If there was any 
indication that the subject had severe cognitive impairment, consent was taken from a 
proxy, usually a next-of-kin or close relative. However, the examination or interview 
was to be interrupted if the participant, in any way, expressed anguish or discomfort, 
regardless of whether the informed consent had been given by the subjects themselves 
or by proxy. All phases of the Kungsholmen Project received approval from the Ethics 
Committee at the Karolinska Institutet, Stockholm, Sweden. 
 Phases I & II (baseline survey): Dnr. 87:148; Dnr. 87:234 
 Phase III (the first follow-up examination): Dnr. 90:251 
 Phase IV (the second follow-up evaluation): Dnr. 94:122 
 Phase V (the third follow-up examination): Dnr: 99:308 
 Death certificate and Inpatient register data: Dnr. 99:025; Dnr. 01:020 
4.2 THE HARMONY STUDY 
Informed consent was required from each participant during the telephone interview 
and again during the clinical phase. The data collection procedures were reviewed and 
approved by the Swedish Data Inspection Board, Stockholm, Sweden, the Regional 
Ethics Committee at Karolinska Institutet, Stockholm, and the Institutional Review 
Board of the University of Southern California. For the HARMONY survey, the 
approval from the Ethics Committee of the Karolinska Institutet was obtained (Dnr: 97: 
051). 
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5 RESULTS 
5.1 OCCURRENCE OF CI 
5.1.1 Prevalence 
In Study I, 4,602 persons with SCI without objective cognitive impairment and 2,927 
cases of CIND were detected. The majority of people with SCI (58%) reported more 
than two complaints, with the most common complaint being “forgetting people’s 
names” (85%), followed by “forgetting words” (49%). On the other hand, most CIND 
cases were mild (78%), having only one cognitive domain impaired. 
Still in Study I, the overall prevalence of SCI was 39% (95% CI 38-39%) and that of 
CIND was 25% (95% CI 24-25%). As shown by the non-overlapping confidence 
intervals, the prevalence of SCI was significantly higher than that of CIND. The 
prevalence of SCI was higher among men compared to women (41 vs. 40 per cent) and 
in people with high compared to low/average educational level (42 vs. 40 per cent), 
high compared to low occupational SES (43 vs. 39 per cent) and in married compared 
to unmarried persons (41 vs. 40 per cent). SCI was also more prevalent in all older age 
groups compared to the youngest, although there was not a linear increase with 
increasing age (prevalence per cent: 65-69 yrs: 37, 70-74 yrs: 43, 75-79 yrs: 45, 80-84 
yrs: 44, 85+ yrs: 40). Prevalence rates of CIND were higher among women compared 
to men (25 vs. 24 per cent) and in people with low/average compared to high 
educational level (27 vs. 15 per cent), low compared to high occupational SES (29 vs. 
19 per cent) and in unmarried compared to married people (27 vs. 23 per cent). 
Similarly to what was observed in SCI, there was not a linear increase in the prevalence 
of CIND with increasing age, CIND was however more frequent in the oldest age 
group compared to the youngest (prevalence per cent: 65-69 yrs: 23, 70-74 yrs: 25, 75-
79 yrs: 24, 80-84 yrs: 25, 85+ yrs: 33). 
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Figure 10. Age- and education-specific prevalence per 100 among women. 
 
 
 
 
          
Figure 11. Age- and education-specific prevalence per 100 among men. 
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In age- and education-specific figures by gender, SCI was more prevalent in higher 
educated women regardless of the age group (Figures 10 and 11). Among men, the 
trend with education was less linear and showed variation between the different age 
groups. On the other hand, CIND was consistently more prevalent among people with 
low/average education compared with people with high education, regardless of both 
age and gender. 
5.1.2 Incidence 
In Study II, during the nine-year follow-up period (4,292 person-years of follow-up) 49 
incident aMCI cases and 145 incident oCIND cases were detected. Overall incidence 
rates were 11.4 (95% CI: 8.6 to 15.1) for aMCI and 33.8 (95% CI: 28.7 to 39.8) for 
oCIND per 1000 person-years. Gender distributions were similar for aMCI (men: 12.5 
[7.2 to 21.5]; women: 11.1 [8.0 to 15.4]) and oCIND (men: 38.4 [28.2 to 52.3]; women: 
32.3 [26.7 to 39.1]). For both men and women, age-specific incidence rates of oCIND 
were higher than those of aMCI. Incidence rates of aMCI and oCIND increased with 
advancing age, for men more than for women, and in oCIND more than in aMCI 
(Figures 12 and 13). 
After correcting for mortality during follow-up, 64 incident aMCI and 196 oCIND 
cases were detected during 4,655 person-years of follow-up. Overall incidence rates of 
aMCI and oCIND increased to 13.7 (10.3 to 18.2) and 42.1 (36.5 to 48.6) per 1000 
person-years. As indicated by age- and gender-specific estimates, corrected and 
observed incidence rates were similar in the younger age groups, but differed among 
people aged 85+ (Figures 12 and 13). 
In Figure 14, aMCI and oCIND groups were merged, and age-specific dementia rates 
were graphed. Compared to observed rates, corrected rates of non-dementia CI showed 
a more linear increase with age and the slope representing CI’s trend with age 
resembled the slope with age of dementia. 
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Figure 12. Age-specific incidence per 1000 person-years of aMCI and oCIND among women. 
Both observed and corrected rates are shown. 
 
 
 
 
 
 
Figure 13. Age-specific incidence per 1000 person-years of aMCI and oCIND among men. 
Both observed and corrected rates are shown. 
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Figure 14. Observed and corrected age-specific incidence per 1000 person-years of 
aMCI+oCIND compared to age-specific incidence rates of dementia. Reprinted with permission 
from Caracciolo et al, Neurology, 200840. 
 
5.2 CORRELATES AND RISK FACTORS FOR CI 
5.2.1 Sociodemographic factors 
In Study I, the results of the GEE models performed on the whole cohort confirmed the 
positive association of SCI with higher education and married status and the negative 
association of these same factors with CIND. In addition, increased odds of SCI were 
observed in all older age groups compared to the youngest old (65-69 years old) while 
in CIND only the oldest old (85+ years old) had increased odds compared to the 
youngest old (Table 5). In models including SES, this factor was associated to 
increased odds of SCI and to decreased odds of CIND, while the association of 
education with SCI was no longer significant (Table 5). A multiplicative positive 
interaction between SES and education was observed for CIND (education*SES: 
B=0.440, p<0.05) but not for SCI. Supplementary analyses (Study I) showed that when 
comparing people with cognitive complaints with and without objective CI, CIND with 
cognitive complaints were significantly older, but similar on the remaining 
sociodemographic characteristics. 
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Table 5. Association of cognitive impairment (CI) syndromes with sociodemographic variables. Odds Ratios or Relative Risks with 95% confidence intervals 
from Generalized Estimating Equations (GEE) models and Poisson Regression. 
 Prevalent Cases Incident Cases 
 SCI CIND aMCI oCIND 
 Model 1 Model 2 Model 1 Model 2 Observed Corrected Observed Corrected 
Age groups        
    65-68 1.0 1.0 1.0 1.0 - - - - 
    70-74 1.3 (1.2-1.4) 1.3 (1.2-1.4) 1.0 (0.9-1.2) 1.1 (0.9-1.2) - - - - 
    75-79 1.4 (1.3.1.6) 1.5 (1.3.1.7) 1.0 (0.8-1.1) 0.9 (0.8-1.1) 1.0 1.0 1.0 1.0 
    80-84 1.4 (1.2-1.6) 1.5 (1.3-1.7) 1.0 (0.9-1.2) 1.0 (0.9-1.2)   1.8 (0.7-5.0) 2.1 (0.8-5.5) 3.8 (1.8-7.9) 4.0 (2.0-8.1) 
    85+ 1.2 (1.0-1.5) 1.3 (1.0-1.6) 1.4 (1.1-1.7) 1.4 (1.1-1.8) 3.1 (1.2-8.2) 3.8 (1.4-10.6) 5.9 (2.9-12.0) 7.2 (3.6-14.3) 
Gender         
    Man 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
    Woman 1.0 (0.9-1.0) 1.0 (0.9-1.0) 1.0 (0.9-1.1) 1.0 (0.9-1.1) 1.2 (0.6-2.3) 1.3 (0.7-2.5) 1.3 (0.9-1.8) 1.4 (1.0-2.0) 
Education        
     Low 1.0 1.0 1.0 1.0 - - - - 
     Average 0.9 (0.9-1.0) 1.0 (0.9-1.1)   1.0 (0.9-1.1) 1.0 (0.9-1.1) - - - - 
     High 1.2 (1.1-1.3) 1.1 (1.0-1.3) 0.5 (0.44-0.58) 0.7 (0.6-0.8) - - - - 
Married        
      No       1.0 1.0 1.0 1.0 - - - - 
      Yes 1.1 (1.0-1.2) 1.1 (1.0-1.2) 0.9 (0.8-0.9) 0.8 (0.7-0.9) - - - - 
SES        
      Low       - 1.0 - 1.0 - - - - 
      High - 1.2 (1.1-1.3) - 0.7 (0.6-0.7) - - - - 
SCI=subjective cognitive impairment; CIND=cognitive impairment no dementia; aMCI=amnestic  mild cognitive impairment; oCIND=other cognitive impairment no dementia; 
Model 1=adjusted for age, gender, education, marital status, zygosity; Model 2= adjusted for age, gender, education, marital status, zygosity, and SES; Observed=observed 
estimates; Corrected: estimates corrected for attrition due to death. 
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Still in Study I, co-twin control Conditional Logistic Regression models on SCI- or 
CIND-discordant twin pairs (n=2,870 and n=2,222) showed confounding by familial 
factors in the association of SCI with education and SES, and in the association of 
CIND with marital status (SCI/high education: OR 1.1, 95% CI 0.9-1.2; SCI/high SES: 
OR 1.1, 95% CI 0.9-1.4; CIND/Married: OR 0.9, 95% CI 0.8-1.1). In contrast, the 
association of CIND with education and SES and that of SCI with marital status were 
still significant (CIND/high education: OR 0.8, 95% CI 0.7-0.9; CIND/high SES: OR: 
0.8, 95% CI 0.7-0.9; SCI/married: OR 1.2, 95% CI 1.0-1.4). 
In Study II, Poisson Regression models confirmed the age and gender trends (Table 5). 
More specifically, we detected a 1.8 (95% CI 1.2-2.7) increased risk of aMCI and a 2.0 
(95% CI 1.6-2.5) increased risk of oCIND for a five-year increment in age. Men had a 
20% higher risk of aMCI and a 30% higher risk of oCIND compared to women, but the 
association was not significant (Table 5). In models corrected for attrition the strength 
of the association with age was enhanced and men were significantly more at risk of 
oCIND compared to women (Table 5). 
 
 
Figure 15. Association of common chronic diseases with subjective cognitive impairment (SCI) 
and cognitive impairment no dementia (CIND). Results from fully adjusted models controlling 
for sociodemographisc, zygosity, chronic diseases, and current affective symptoms. Numbers 
bolded refers to associations with p<0.05. 
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5.2.2 Chronic diseases and multimorbidity 
In Study III, GEE models (adjusted for sociodemographics and zygosity) were 
performed in the whole cohort and showed positive associations of circulatory, 
musculoskeletal, respiratory, endocrine, gastrointestinal, urological diseases and 
malignancy with SCI. Similarly, circulatory, musculoskeletal, respiratory, endocrine 
and urological diseases were significantly associated with increased odds of CIND. In 
fully adjusted models further controlling for other diseases and current affective 
symptoms, the associations of endocrine diseases and cancer with SCI and that of 
circulatory disease with CIND were no longer significant (Figure 15). 
There was also a significant dose-dependent relationship between number of chronic 
diseases and odds of SCI, while in CIND this effect was less evident. Multimorbidity, 
defined as the co-occurrence of two or more chronic diseases in the same individual, 
was present among 61% (n=2,817) of people with SCI, compared to 58% (n=1,616) of 
CIND and 49% (1,895) of NCI people. In GEE models, multimorbidity was associated 
with SCI and CIND after basic (SCI: OR 2.0, 95% CI 1.8-2.3; CIND: OR 1.5, 95% CI 
1.3-1.8) and full adjustment for potential confounders (SCI: OR 1.9, 95% CI 1.7-2.2; 
CIND: OR 1.4, 95% CI 1.3-1.7). 
Still in Study III, in co-twin control Conditional Logistic Regression models on SCI- or 
CIND-discordant twin pairs (n=1,720 and n=926), the associations of chronic diseases 
with CIND were no longer significant, with the exception of cancer (OR 1.7, 95% CI: 
1.0-2.7). In contrast, the associations of SCI with most chronic diseases, including 
circulatory (OR 1.3, 95% CI: 1.1-1.7), musculoskeletal (OR 1.5; 95% CI: 1.2-1.8), 
respiratory (OR 1.5, 95% CI: 1.1-2.2), gastrointestinal (OR 1.8, 95% CI: 1.4-2.8) and 
urological (OR 1.4, 95% CI: 1.1-1.7) diseases were unchanged. The dose-dependent 
association with the number of chronic diseases could still be observed for SCI but not 
for CIND. Similarly, multimorbidity was still associated with SCI (OR 1.9, 95% CI 
1.4-2.6) but no longer with CIND (OR 1.3, 95% CI 0.9-2.0). 
5.2.3 Familial factors 
In Study I, concordance rates for SCI and CIND were similar in monozygotic and 
same-sex dizygotic twins and were lower in unlike-sex dizygotic twins (Table 6). These 
patterns were confirmed by tetrachoric correlation coefficients, which did not 
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significantly differ between monozygotic and same-sex dizygotic twins. In unlike-sex 
dizygotic twins the correlation coefficients were lower compared to both monozygotic 
and same-sex dizygotic twins. 
Table 6. Probandwise concordance rates and tetrachoric correlations for monozygotic, 
dizygotic same-sex, and dizygotic unlike-sex twins in subjective cognitive impairment (SCI) and 
cognitive impairment no dementia (CIND). 
 Monozygotic  Dizygotic  Unlike sex 
 Probandwise 
Concordance 
Rates 
Tetrachoric 
Correlations 
(95% CI) 
 Probandwise 
Concordance 
Rates 
Tetrachoric 
Correlations 
(95% CI) 
 Probandwise 
Concordance 
Rates 
Tetrachoric 
Correlations 
(95% CI) 
SCI 52 0.24 
(0.18-0.30) 
 51 
 
0.22 
(0.17-0.27) 
 43 0.04 
(0-0.10) 
CIND 31 0.23 
(0.16-0.28) 
 29 0.17 
(0.12-0.22) 
 26 0.09 
(0.04-0.14) 
5.2.4 Low mood 
In Study IV, during the 3,711.5 person-years (minimum 1.2; maximum 8.2) of follow-
up, 160 persons developed MCI. Of these, 40 were classified as aMCI and 120 as 
oCIND. Fifty-three percent (n=21) of aMCI and 31 percent (n=37) of oCIND occurred 
in people with baseline low mood (LM). When considering aMCI and oCIND together, 
the incidence of MCI in people with baseline LM was about 2.5 times higher than that 
detected among persons without baseline LM. This ratio was constant across both 
waves of examinations. Cox regression analysis performed using data from both waves 
and adjusted for sociodemographic characteristics confirmed the increased risk of all 
outcomes in relation to the presence of baseline LM, although the association was 
stronger for aMCI. Adjustment for other covariates, including follow-up LM, history of 
psychosis, psychotropic drug use, ApoE-ε4 allele, history of cerebrovascular disease, 
heart disease, diabetes, high blood pressure, hip fracture, multimorbidity, and 
polypharmacy, did not substantially change the results. Stratified analyses showed that 
the increased risk of aMCI and oCIND associated with baseline LM was neither 
substantially modified by follow-up LM nor by the other  factors  (as listed above).  
However, an  additive  interaction  was found between baseline LM and ApoE-ε4 allele 
for  the  risk  of  developing aMCI (Attributable Proportion: 0.5, 95% CI: 0.1-0.96), but 
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Figure 16. Hazard ratios with 95% confidence intervals of baseline low mood in relation to the 
development of amnestic mild cognitive impairment (aMCI), other cognitive impairment (oCIND) 
and all cognitive impairment (All-CI). Models are adjusted for age, gender, and education. 
not for the risk of developing oCIND. No other interactions were observed. 
During the follow-up, 158 cognitively healthy persons developed dementia bypassing 
MCI. In these people, the HR of low mood was 1.6 (95% CI 1.1-2.3) after adjustment 
for age, sex, and, education. Further adjustment for other covariates did not affect the 
relationship of dementia with baseline LM. However, the association was no longer 
significant after adjustment for follow-up LM (HR 1.4, 95% CI 0.9-2.0). 
5.3 PROGRESSION TO DEMENTIA 
5.3.1 Low mood 
In Study IV, during the 1,354.8 person-years (minimum 0.7; maximum 4.5) of follow-
up, 50 people with MCI progressed to dementia. Eleven  cases  of dementia occurred in 
people with aMCI and 39 cases of dementia occurred in people with oCIND. Among 
the aMCI persons who progressed to dementia, eight (70%) had baseline LM, detected 
before the development of aMCI, and three (27%) had follow-up LM, which was 
detected  at  the  time  of  aMCI  classification.  Among  the  oCIND  that progressed to 
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Figure 17. Hazard ratios with 95% confidence intervals of baseline low mood in relation to the 
progression to dementia of amnestic mild cognitive impairment (aMCI), other cognitive 
impairment (oCIND) and all cognitive impairment (All-CI). Models are adjusted for age, gender, 
and education. 
 
people with aMCI and 39 cases of dementia occurred in people with oCIND. Among 
the aMCI persons who progressed to dementia, eight (70%) had baseline LM, detected 
before the development of aMCI, and three (27%) had follow-up LM, which was 
detected at the time of aMCI classification. Among the oCIND that progressed to 
dementia, 14 (33%) had baseline LM and six (15%) had follow-up LM. Cox regression 
analysis confirmed the association of baseline LM with an increased risk of progression 
to dementia in people with aMCI, but not in those with oCIND (Figure 17). Only for 
aMCI, the association was strengthened after further adjustment for ApoE-ε4 allele. 
Adjustment for other factors did not substantially change the association. On the other 
hand, follow-up LM was not associated with an increased risk of progression to 
dementia in people with aMCI or in people with oCIND. 
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6 DISCUSSION 
6.1 SUMMARY AND INTERPRETATIONS OF THE FINDINGS   
6.1.1 Occurrence of CI 
In Study I, the overall prevalence of SCI and CIND was 39% and 25%, respectively. 
These figures are within the 25-57% and 5-32% ranges previously reported for 
cognitive complaints145, 150-153 and CIND.35, 37-39, 47-49, 54, 174 Notably, our estimates of 
CIND were similar to those reported by the Canadian Study of Health and Aging,174 
which used operational criteria close to those adopted in the present study. SCI was 
significantly more common than CIND in the nondemented elderly population. 
Although the cross-sectional study design does not allow clear inferences concerning 
SCI progression, the higher frequency of SCI compared with CIND may imply that not 
all people with SCI will develop objective cognitive impairment. 
In Study II, the overall incidence rates of aMCI and oCIND were 11.4 and 33.8 per 
1000 person-years. The observed aMCI incidence rates were similar to those reported 
by the MoVIES,110 LEILA75+177 and PAQUID180 studies. The higher figures reported 
in the ILSA50 and CAIDE51 studies may be due to differences in the operationalization 
criteria. For oCIND, comparison with other studies is not possible as no incidence 
estimate of CIND/oCIND has been previously reported. After correction for attrition 
due to death, incidence rates of both aMCI and oCIND increased to 13.7 and 42.1 per 
1000 person-years, respectively. This finding shows that disregarding the effect of 
mortality during follow-up when estimating the incidence of non-dementia CI leads to 
an underestimation of approximately 20%. 
The prevalence of SCI unlike that of CIND increased with increasing age, although 
both SCI and CIND were more prevalent among the oldest old (Study I). Our 
observation of a lack of a clear trend with age in prevalent estimates of CIND is in 
line with some population-based studies,39, 48 while differs from others.36, 37, 54  The 
discrepancies can be explained by differences in the operationalization of CIND. 
More specifically, the lack of a trend with age could be due to the use of internal 
rather than external reference populations43 when correcting CIND scores by age. 
Indeed, age is going to be leveled out when the reference is the same population 
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measured at the same time point as the ongoing study. This is confirmed by the 
observation that the majority of studies reporting an increase in the prevalence of 
CIND with age used an external reference population to define normative cut-offs for 
different tests.35, 36, 54 Another possible mechanism at work can be selective survival. 
If older people with CIND are more likely to die, a snapshot of the population such as 
that carried out in prevalence estimates would not detect an increase with age. The 
estimates resulting from the longitudinal observation of people without CI at baseline 
are more reliable. Indeed, a clear age-related increase in the prevalence of both aMCI 
and oCIND was detected using incident cases (Study II). The trend with age for 
incident non-dementia CI was more evident after correction for attrition due to death. 
This may also be attributable to the effect of selective survival, which can level out the 
incidence curve in old ages. 
6.1.2 Correlates and risk factors for CI 
6.1.2.1 Sociodemographic factors 
In Study I, older age groups had 20 to 30 per cent increased odds of SCI compared to 
the youngest old (age 65-79) while a 40% increase in the odds of CIND was observed 
only among the oldest compared to the youngest old. These findings are in agreement 
with the most of previous studies on cognitive complaints, which reported an 
association with older age.145, 150-155 As discussed above, population-based studies using 
prevalent cases of CIND reported contradictory findings regarding an association with 
age.35-37, 39, 48, 54, 63 In Study II, a two-fold increased risk of incident CIND for a 5-year 
increase in age was detected. Comparison with other studies is difficult, as no previous 
report has investigated the effect of age on CIND longitudinally. Older age was also 
associated to an 80 per cent increased risk of incident aMCI (Study II). This is in line 
with most incidence studies on aMCI, which reported a positive effect of age.50, 51, 80, 178 
No clear effect of gender was observed on prevalent or incident estimates of non-
dementia CI (Studies I and II). However, a significant 40 per cent increased risk of 
oCIND was detected after correction of incidence estimates for attrition due to death 
(Study II). It is possible that non-dementia CI might be more common in men that in 
women.52, 110 The lack of association or association with female gender reported by 
most prevalence35-37, 39, 48, 54, 63, 163, 182, 184, 188, 189 and incidence50, 51, 80, 177, 178, 180, 182 
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studies may, once again, be explained by selective survival. Indeed, men generally 
have higher mortality rates compared to those in women, especially in older ages. 
Sex-specific mechanisms can underlie the higher occurrence of non-dementia CI in 
men compared to women. It is well documented that women are at increased risk of 
dementia compared to men, especially after age 85.4 This effect can be due to a faster 
progression of women with neurodegenerative brain pathology from normal cognitive 
functioning to overt dementia syndromes.234 On the other hand, men may be more 
exposed than women to other risk factors, which could be related to a slower 
progression from normal cognitive functioning to dementia.52 Therefore, men, as 
opposed to women, could experience a longer transitional period in an intermediate 
stage of non-dementia CI. 
In Study I, education was the most relevant sociodemographic factor in relation to 
prevalent CIND. After adjustment for age, gender, and marital status, higher 
education was associated to a 50% decrease in the odds of CIND. When occupational 
SES was also taken into account, the effect was attenuated to a 30% decrease in the 
odds of CIND. This finding is in line with the majority of studies on CIND, which 
found a negative association of higher education with CIND.35, 37, 39 
Decreased odds of CIND were observed in people who were married and had higher 
occupational SES. Also these findings are in line with previous reports.47, 54-56 A 
reverse pattern was observed for SCI, with increased odds associated to higher 
education, married status, and higher occupational SES. Most previous studies on 
cognitive complaints regardless of objective CI are in contrast with our current 
findings on education and SCI.151, 153, 155, 157, 158 On the other hand, in a study which did 
not include objective CI, SCI was more prevalent among highly educated people.160 
The discrepancies between studies on cognitive complaints, as well as the reverse 
pattern observed for SCI and CIND in Study I, can be explained with the cognitive and 
brain reserve hypothesis.235 Indeed, older people with higher education and SES, and 
who are married may be protected against overt cognitive impairment even in the face 
of initial loss of brain integrity because of improved use of cognitive strategies (high vs. 
lower education), improved lifestyle (high vs. lower SES) and richer social network 
(married vs. unmarried). In people with high cognitive and brain reserve, cognitive 
complaints, rather than objective CI, may be among the first signs of underlying 
neurodegeneration.236-238 An alternative hypothesis might be that people with higher 
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education, higher SES, and who are married may take a greater interest in their health 
and be more aware of even minimal cognitive changes. This is in agreement with 
findings showing that people with richer social networks have higher odds of SCI150 
and that people with higher education had a lower chance of anosognosia of their 
cognitive deficits.239 However, additional analyses stratified by CIND showed no 
difference in education, SES, or marital status when directly comparing subjects with or 
without cognitive complaints, suggesting that the pattern of associations observed for 
SCI are essentially driven by the comparison with CIND (Study I). 
Still in Study I, co-twin control analysis showed confounding by familial factors in the 
association of SCI with education and SES and in that of CIND with marital status. On 
the other hand, the association of CIND with education and SES and that of SCI with 
marital status were unchanged. These results suggest that genetic background and early 
life environment may play a role in the association of sociodemographic factors with 
SCI, rather than with CIND. Indeed, people with SCI had higher education and 
occupational SES. This implies that people with SCI, as opposed to people with CIND 
of the same age and education, were more likely to come from families with higher 
SES and to have higher baseline intelligence, a characteristic strongly influenced by 
genetic background.240 The relationship between adult life academic and occupational 
attainment with intelligence and parental SES is confirmed by a meta-analysis 
conducted on 83 longitudinal studies.241 On the other hand, in the case of CIND, 
familial factors explained the positive association with unmarried status. This may 
suggest that some other characteristics, also strongly influenced by familial factors, can 
determine both marital status and CIND in late life. One possible candidate is 
personality traits.242 Indeed, neuroticism has been linked to both accelerated cognitive 
decline243 and higher rates of divorce.244 
6.1.2.2 Chronic diseases and multimorbidity 
In Study III, most common chronic diseases were associated with increased odds of 
subjective and objective CI. More in detail, both SCI and CIND were related to 
mental, musculoskeletal, respiratory, and urological diseases. Although clusters of 
diseases have been investigated sparsely in relation to subjective or objective cognitive 
impairment, available data support our findings. Notably, mental diseases have been 
associated to both SCI and CIND and there is agreement as to the complex relationship 
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between psychiatric conditions and subjective and objective cognitive functioning.64, 77, 
140, 145 Regarding musculoskeletal diseases, the relationship between osteoporosis, hip 
fracture and cognitive decline is well known albeit not yet well understood,64, 245 
whereas articular diseases are associated with chronic pain, which has been related to 
cognitive complaints153 and slower cognitive processing speed.246 Our findings of an 
association of SCI and CIND with respiratory and urological diseases are in agreement 
with previous reports linking asthma and COPD to cognitive impairment69, 70 and with 
the growing evidence of an association between chronic kidney disease and reduced 
cognitive performance.71, 72 
SCI, but not CIND, was associated with circulatory and gastrointestinal diseases. With 
regard to circulatory diseases and SCI, our results are at odds with a study which failed 
to find an association between SCI and any specific circulatory diseases,159 but are in 
agreement with a report on improved subjective cognitive functioning after successful 
coronary bypass surgery.247 The present findings of a lack of association of circulatory 
diseases with CIND is in line with some55, 64 but in disagreement with other sets of 
evidence.49, 55, 248 The discrepancies can be explained by alternative operationalizations 
of CIND, different severity and types of circulatory disease, as well as heterogeneity in 
study populations. On the other hand, gastrointestinal diseases have generally been 
neglected in their relation to cognition. One exception is the known association of 
impaired cognition with severe liver disease and, according to recent research, also with 
mild biliary cirrhosis.73 Our findings of an association with SCI can imply that 
gastrointestinal diseases have an impact on sub-clinical forms of cognitive impairment. 
CIND, but not SCI, was associated with endocrine diseases. This is in agreement with 
previous studies, which reported a positive association between diabetes and thyroid 
dysfunction with cognitive impairment.55, 74 The lack of association of endocrine 
diseases with SCI may be explained by the severity of the cognitive deficits linked to 
this type of somatic conditions, which may make it more probable for subjects with 
endocrine diseases to be in the CIND rather than the SCI category. 
Finally, no association with malignancy was found in either SCI or CIND when 
considering unmatched analysis conducted on the whole cohort. This is in line with 
some reports76 but at odds with other investigations that focused on the relationship 
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between specific cognitive functions and types of cancer,76 aspects not investigated in 
Study III. 
A dose-dependent effect in the relationship of chronic diseases with SCI and CIND was 
observed. This relation was linear in SCI but not in CIND. In particular, multimorbidity 
defined as having at least two chronic diseases, was associated with 100% increased 
odds of SCI and to 50% increased odds of CIND, after adjustment for potential 
confounders including current affective symptoms. These findings are in agreement 
with previous studies which reported a positive association between cognitive 
complaints and CIND with poor health and multimorbidity.56, 61, 64, 161, 249 
After controlling for familial factors, the association of CIND with malignancy was 
strengthened and reached significance. This suggests that the effect of cancer on 
cognition may be mediated by environmental factors related to adult life and also 
confirms the results of a previous study on a smaller sample of Swedish twins, which 
reported an association between cancer and cognitive dysfunction when familiar 
factors were taken into account.75 On the other hand, control for familiar factors 
attenuated the association of CIND with all other disease clusters, including mental, 
musculoskeletal, respiratory, endocrine, gastrointestinal and urological diseases. This 
indicates a role of genetic background and early life environment in determining the 
relationship of CIND with most chronic diseases. Conversely, the association of SCI 
with circulatory, musculoskeletal, respiratory, gastrointestinal and urological diseases 
was not influenced by familial factors. This implies that, at least at the level of SCI, 
adult life environments play the major role in determining an association with chronic 
diseases. 
Both general and specific mechanisms may lie behind the association of SCI and CIND 
with chronic diseases observed in Study III. Examples of specific mechanisms are low 
oxygen levels in chronic respiratory diseases, insulin resistance in diabetes, and thyroid 
hormones deficiency or excess in thyroid dysfunction, all conditions which can directly 
affect the brain. On a more general level, both physical and mental co-morbidities can 
generate tiredness and lack of concentration, possibly resulting in the subjective feeling 
of “not being as sharp as before” and in eventual impaired cognitive performance. 
Another mechanism that may be involved is the reduction in functional independence 
associated with several chronic diseases and the consequent reduction in leisure and 
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social activities, known protective factors for cognitive decline.250 Moreover, several 
chronic conditions can reduce the amount or the quality of sleep, with known reduced 
cognitive efficiency251 and long-term increased risk of cognitive impairment.252 In 
addition, chronic stress may accompany chronic diseases and impact on the brain 
through the imbalance of the adrenocortico axis.253 It has also been suggested that both 
circulatory and kidney diseases might impact on the brain through microvascular 
damage,76 while a possible cytokine activated immune system dysregulation in the 
brain may be a common response to inflammation or injury in any organ system in the 
body.76  
6.1.2.3 Familial factors 
In Study I, probandwise concordance for SCI was higher than that of CIND, indicating 
a more prominent role of familial factors in subjective rather than objective cognitive 
impairment. However, tetrachoric correlation coefficients were similar between SCI 
and CIND and were all below 0.25, indicating a poor association of familiar factors 
with both SCI and CIND. In particular, both probandwise concordance rates and 
tetrachoric correlation coefficients did not differ between monozygotic and same-sex 
dizygotic twins, suggesting a limited contribution of genetic background to both SCI 
and CIND. This is in line with previous findings on cognitive dysfunction.254 Both 
concordance rates and tetrachoric correlation coefficients for SCI and CIND were 
lower in unlike-sex dizygotic twins compared to monozygotic and same-sex dizygotic 
twins, pointing to a possible gender effect. 
6.1.2.4 Low mood 
In Study IV, low mood reported three years before MCI detection substantially 
increased the risk of developing MCI. In particular, low mood was associated with a 
5.8-fold increased risk of aMCI, a 2.2-fold increased risk of oCIND, and a 2.7-fold 
increased risk of All-MCI (aMCI+oCIND), after adjustment for sociodemographic 
factors. These findings are in line with previous evidence from other longitudinal 
studies.60, 82, 130, 255, 256 The excess risk of aMCI associated with low mood was almost 
triple that for oCIND (HR 5.8 versus 2.2), suggesting the presence of a gradient in the 
relationship between low mood and cognitive impairment severity. Indeed, in our study 
the definition of amnestic MCI excluded people with global cognitive impairment 
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(MMSE mean=26). On the other hand, oCIND included more severely impaired cases 
with global cognitive impairment (MMSE mean=21), who did not fulfill criteria for 
dementia. In addition, we also observed a group of people who rapidly progressed to 
dementia, bypassing MCI (MMSE mean=8), for whom the excess risk associated with 
low mood was 60%, lower than that observed in both aMCI and oCIND. 
Also in Study IV, a synergistic interaction of low mood and ApoE-ε4 was observed, 
with increased risk of aMCI in people with both baseline low mood and at least one 
ApoE-ε4 allele. This is in line with results from a study on primary care patients256 and 
supports the hypothesis that low mood may be related to AD-type neuropathology.257, 
258 Conversely, none of the other factors under investigation interacted with low mood. 
In particular, no modification of the relationship of baseline low mood with MCI was 
observed when taking into account history of psychosis, psychotropic drug use, and 
vascular factors. Indeed, low mood in prodromal MCI can be independent from history 
of depression.256 It has also been reported that depressive symptoms in MCI are 
particularly resistant to treatment.106, 259 On the other hand, the lack of interaction of 
low mood with vascular factors confirms previous findings from the Cardiovascular 
Health Study and does not support the “vascular depression hypothesis”.82, 260 
6.1.3 Progression to dementia 
Low mood was associated with a 5.3-fold increased risk of progression to dementia in 
people with aMCI (Study IV). This finding is in line with some studies on the 
progression of MCI62, 128-130 and is at odds with others.132, 133, 135, 136, 261 Indeed, most of 
the studies that found no or inverse association focused on depressive symptoms 
measured at the same time as MCI detection.133, 135, 136, 261 The current findings showed 
that only low mood measured at baseline, three years before the detection of MCI, 
predicted subsequent progression of MCI to dementia. Conversely, low mood that co-
occurred with MCI did not predict further progression to dementia. These results 
support the hypothesis that the symptom of low mood may be relevant in the prodromal 
stage of MCI, losing its importance at more advanced stages, when the cognitive 
deficits are already manifested. Our results do not confirm previous evidence from a 
report based on the Religious Order Study,132 which found no increase in depressive 
symptoms in the prodromal stage of dementia. Indeed, the generalizability of those 
Discussion 
75 
results has been questioned, as religious order people might have higher resilience to 
depressive symptoms.262 
The observed effects of low mood on the development and progression of non-
dementia CI can have different explanations. One possibility would be that low mood is 
a risk factor for cognitive impairment and particularly memory functioning, which 
would likely be mediated by the interplay between psychosocial stress and the activity 
of the adreno-cortico-axis, whose imbalance has known effects on neurogenesis and 
hippocampal physiology.263 An alternative explanation would be that low mood and 
MCI share a common neuropathogenic substrate. In this case the narrow time frame 
that we observed for the relationship between low mood and cognitive decline could be 
explained by the stage of the underlying neurodegenerative process. In earlier stages, 
when cognitive deterioration is not yet manifest, low mood could be one behavioral 
sign of neurodegeneration, as in the concept of “amyloid-associated depression”.258 In 
more advanced stages, when the neurodegeneration has become more pervasive, MCI 
could represent a later manifestation of the process leading to dementia. 
Low mood is not the only risk factor that has been investigated by our group in relation 
to the progression of CI syndromes to dementia. Table 7 lists the latest reports on this 
topic from the Kungsholmen Project and collaborative studies. 
Table 7. Latest reports from the Kungsholmen Project and collaborative studies on risk factors 
for progression of CI syndromes to dementia. 
Authors Study Factors 
Caracciolo et al264 Kungsholmen Project Feelings of loneliness versus social isolation 
Caracciolo et al265 Kungsholmen Project Multimorbidity 
Xu et al123 Kungsholmen Project Diabetes and prediabetes 
Xu et al266 Kungsholmen Project APOE-ε4 
Clerici et al267 Milan Clinical Study Vascular risk factors and white matter lesions 
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6.2 METHODOLOGICAL CONSIDERATIONS 
6.2.1 Generalizability 
The Kungsholmen population consisted of individuals aged ≥75 years that were living 
in a geographically defined central area of Stockholm. This population had comparable 
age and sex compositions as well as access to a similar health care system in 
Stockholm. However, the Kungsholmen population did differ from the rest of the urban 
area of Sweden in terms of the proportion of pensioners, women, highly educated 
persons, and marital status. Caution is needed when generalizing the findings from the 
Kungsholmen population to a younger population or to rural areas. The major findings 
from this population may be generalized to the urban population aged over 75 in 
Western society. 
The HARMONY population included twins aged ≥65 years derived from the Swedish 
Twin Registry that covers the whole of Sweden. If twins are different from the general 
population (non-twins) in terms of the outcome of interest, the results will not be 
applicable to the general population. However, the prevalence of CIND in this 
population was similar to that reported in the CSHA, which was based on the general 
elderly population. Moreover, it has been previously reported that the prevalence of 
dementia detected in HARMONY was similar to that reported in the Kungsholmen 
population.216 It has also been shown that twins surviving into later life are similar to a 
representative sample of non-twins of the same age in terms of health status and 
behavioral functioning.268 Nevertheless, the comparison of the results from the cohort 
as a whole with the matched pairs provides important information about the potential 
role of genetic and familial influences. The major findings from this population may 
also be generalizable to a population aged 65 years and older in Western society. 
6.2.2 Internal validity 
Besides generalizability issues, internal validity is another aspect that can strongly 
impact on the quality of epidemiological investigations. Indeed, in both the 
Kungsholmen Project and the HARMONY Study, the possibility of a partial 
misclassification of both the outcomes and the exposures cannot be ruled out. 
Moreover, residual confounding from factors which have not been taken into account is 
unavoidable in observational research. 
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6.2.2.1 Outcomes 
In the Kungsholmen Project (Studies II and III) non-dementia CI was defined as aMCI 
and oCIND. Both definitions rely on current criteria for CI. Specifically, aMCI focuses 
on memory deficits in persons with otherwise preserved general cognitive and daily life 
functioning,45 whereas oCIND matches up with a global characterization of CIND, 
based on a cognitive screening measure such as the MMSE.33, 38 Although widely used, 
these definitions of cognitive impairment are mere approximations of the true 
phenomenon. Indeed, aMCI was operationalized based on one single measure of 
episodic memory and a cut-off of minus 1.5 SD, which showed low sensitivity for pre-
clinical dementia.269 Furthermore, such criteria can guarantee extremely high 
specificity269 and almost zero probability of “going back to normal”.214 In other words, 
while we are almost certain that our aMCI cases were truly cognitively impaired, by 
using only the aMCI definition we would have classified a considerable proportion of 
people with CI as unimpaired. That was the rationale behind the choice of using an 
ancillary definition of CI, oCIND. The term oCIND was adopted to emphasize the fact 
that this category included people with global CI who were excluded by definition from 
the aMCI category. The choice of a cut-off of minus 1 SD for oCIND aimed at 
increasing the sensitivity of the definition and additionally to capture people with slight 
global cognitive impairment. Moreover, oCIND was based on the MMSE, which has 
recently shown good sensitivity and specificity for non-dementia CI.206 Nonetheless, it 
is probable that even after combining the two definitions of aMCI and oCIND some 
cases of CI were left undetected. Specifically, aMCI and oCIND did not include 
isolated non-memory CI. However, the validity and predictivity of this type of 
cognitive deficits is still undergoing debate. In a follow-up of people with MCI sub-
types defined according to the revised Mayo criteria, naMCI-single was the most 
unstable group and had an extremely high probability of reverting to normal cognitive 
functioning after a one and a half years.214 
Another aspect that may have reduced the validity of our estimates is the relatively long 
3-year time interval in between follow-ups. During this time a variable proportion of 
subjects may develop CI and progress to dementia. These persons, who were classified 
as unimpaired at the previous evaluation, will be diagnosed as demented at follow-up, 
apparently “bypassing” the non-dementia CI stage. A closely related phenomenon is 
the possible death of people who developed CI during the follow-up intervals. Again, 
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non-dementia CI will not be detectable at follow-up examinations and this would 
further bias incidence estimates. In Study II, we corrected for attrition due to death by 
imputing the cognitive status of subjects who died without a dementia diagnosis and 
who were not previously classified as non-dementia CI. However, this did not correct 
for the possible bias associated to the rapid transition to dementia in people who were 
cognitively intact at baseline. The possible consequences are in the direction of an 
underestimation of both the occurrence of non-dementia CI (Study II) and related 
estimates (Study IV). 
In the HARMONY Study (Studies I and III), non-dementia CI was defined as SCI and 
CIND. Although the definition of CIND was based on current criteria for CIND,36, 37, 46 
there is currently no agreement as to the definition of SCI.270 Specifically, different 
assessment questions have been used in different studies to detect subjective cognitive 
complaints and validation studies have been sparse.270 A few standardized 
questionnaires on cognitive complaints have been devised, none of which is widely 
adopted or highly validated.270 In comparison with other investigations, the question on 
subjective cognitive complaints adopted in the HARMONY study may be particularly 
promising, although this possibility is yet to be tested. Indeed, the question included an 
enquiry about a change in memory (not just a “memory problem”), referred to a 
specific time-frame (“have you noticed any change in your memory in the last three 
years?”). This type of formulation may have captured the initial deterioration in 
cognitive abilities experienced both in normal and accelerated cognitive aging. One 
limitation regards the generalizability of a question about memory to any cognitive 
problem. It has to be considered that elderly people do not generally have informed 
knowledge on cognitive processes and that, in their naïve jargon, the term “memory” is 
often used as a passe-partout for any cognitive impasse. This is supported by the 
frequencies of specific “memory” problems reported in HARMONY by subjects with 
SCI. Indeed, the most common complaints (“forgetting names”, “forgetting words”) 
regarded the language, rather than memory, domain.  
CIND definition in HARMONY was based on impairment on any test of a telephone 
cognitive screening (TELE). The validity of this telephonic evaluation has been 
previously evaluated, showing satisfactory psychometric properties when used to 
identify possible dementia cases.218 Although the sensitivity and specificity of TELE 
for non-dementia CI is yet to be tested, our estimates of the prevalence of CIND based 
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on the cognitive tasks included in TELE are identical to those reported by the CSHA, 
which employed a full neuropsychological battery coupled with clinical in-person 
evaluation of the cases.174 To define impairment on the single tasks of TELE, a cut-off 
of minus 2 SD was used. Indeed, the short format of the cognitive tests included in 
TELE tended to generate a ceiling effect in subjects’ performances. While a 
conservative cut-off may have caused the exclusion of very mild cases of CIND, this 
choice is justified by the necessity of balancing false negatives and false positives. 
Nonetheless the relatively high prevalence of CIND reported in Study I suggests that 
the false negatives, although undoubtedly present, may not have been over-represented 
using the current operationalization. 
6.2.2.2 Exposures 
The accuracy and validity of the measures used to define the exposures under study are 
also a possible source of bias and can strongly influence the internal validity of a 
scientific investigation. Across all studies (Studies I-IV) classification accuracy of 
sociodemographic variables was guaranteed by the careful work of the respective 
research teams for the Kungsholmen Project and the HARMONY Study. In particular, 
in both projects, the variable education underwent through several revisions. In the 
HARMONY Study (Studies I and III), the latest revision of the variable education was 
used. In the Kungsholmen Project, an earlier categorization of the variable was adopted 
in Study II, while a revised categorization was used in Study IV. Changes originated 
from a conceptual discussion within the research team, which led to the reclassification 
as low educated of people with professional education. This change slightly affected 
CIND and MCI categories, with subsequent minor changes in the classification of the 
study populations between Study II and Study IV. 
In both the HARMONY Study and the Kungsholmen Project, multiple indicators of 
medical morbidity were used. This was done to limit misclassification, which is often 
the case when using a single source of information. In particular, all chronic diseases 
investigated in Study III were derived from a combination of information coming from 
national inpatient registers and self- and informant-reports. Possible limitations are that 
neither disease severity nor disease duration was taken into account. Moreover, the 
ascertainment of the cases was cross-sectional. As a consequence, our current estimates 
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on the association of chronic diseases and multimorbidity with non-dementia CI have 
to be interpreted as rough approximations of the true phenomenona.  
In Study IV, the main exposure was a single depressive symptom, low mood, evaluated 
using a single question and gathered from different questionnaires at KP baseline and 
follow-ups. However, the baseline question had the highest loadings on a depression 
factor extrapolated from the general health interview it belonged to, whereas, at follow-
ups, low mood item was part of a standardized and validated psychiatric battery. The 
comparability of the two instruments in measuring the same symptom is supported by 
the similar incidence rates of low mood at first and second follow-ups. In addition, 
although no severity grading of the symptom of low mood was performed at the KP 
baseline evaluation, this information was available at follow-ups. Although these 
elements support the validity of the current assessment of low mood, a measure based 
on answers to multiple similar questions on low mood would increase reliability of the 
estimates. 
6.2.2.3 Confounders 
Several confounders have been taken into account in the four studies of this thesis. In 
Studies I and III, special attention has been devoted to the careful control of the role of 
genetic background and early environment on estimates of non-dementia CI and 
additionally on its association with other factors, namely sociodemographic variables 
and chronic diseases. 
Other major confounders taken into account were somatic and psychiatric co-
morbidity, social integration, and APOE-ε4 in Studies II and IV, as well as affective 
disorders in Study III. 
There are, however, several other possible confounders that could not be taken into 
consideration. Specifically, the possible effects of personality traits and premorbid 
intelligence were not evaluated. Information on baseline intelligence is relevant when 
cross-sectionally evaluating the presence of objective CI and can help discriminate 
between individual differences in intellectual abilities and CI as a result of cognitive 
decline.269 On the other hand, personality traits have been repeatedly associated to 
subjective CI and some evidence suggested their possible role as moderators of the 
effect of depression on cognitive impairment.161-164, 271 Other confounders, particularly 
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relevant to Study IV, are recent life events and a history of depression. The first factor 
can be related to late-life depressive symptoms and the second can indicate a longer 
exposure and proneness to depressive symptoms. While stressful life events were not 
taken into account in the present thesis, we adjusted for history of depression. 
Nonetheless, as our diagnoses were registry-based, an underestimation of the effect of 
history of depression on the association of low mood with non-dementia CI cannot be 
ruled out. 
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7 CONCLUSIONS 
7.1 GENERAL CONCLUSIONS 
Cognitive impairment is highly frequent in the elderly population. The prevalence of CI  
increases with age, especially when the rates are detected longitudinally and corrected 
for attrition. Other sociodemographic factors may also affect the distribution of CI 
among nondemented people. Co-morbid chronic diseases and multimorbidity are 
associated to increased odds of subjective and objective CI, while low mood is a strong 
predictor of CI development and progression to dementia in the cognitively healthy 
elderly. Familial factors may contribute to non-dementia CI in a complex fashion. 
7.2 SPECIFIC CONCLUSIONS 
1. Subjective and objective cognitive impairment are both highly prevalent among 
the nondemented elderly yet have distinct sociodemographic profiles. Familiar 
factors play a relatively limited role in determining SCI and CIND but can 
partly explain the association of SCI and CIND with sociodemographic factors. 
2. The incidence of cognitive impairment is high among the nondemented elderly, 
and increases with age. Estimates are higher when corrected for attrition due to 
death, especially in the oldest old and in men. Comparison with estimates of 
dementia showed a similar trend with age only after correction. 
3. Several chronic diseases are associated with both subjective and objective CI 
and the association is stronger when chronic diseases co-occur. Genetic and 
early-life environmental factors may partially explain the association of CIND, 
but not that of SCI, with chronic diseases and multimorbidity. 
4. Low mood is more strongly associated with amnestic than with global CI. 
Progression toward dementia is predicted by low mood manifest in the 
prodromal stage of non-dementia CI but not by low mood co-occuring with CI. 
These findings indicate that low mood is particularly prominent in the very 
early stages of cognitive decline. 
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8 RELEVANCE AND IMPLICATIONS 
We showed that non-dementia CI is highly frequent among the nondemented elderly, 
especially after correction for attrition due to death and when taking into account also 
subjective CI. The relatively low contribution of familial factors to SCI and CIND 
suggests a role of adult life environments in the development of CI. 
We found that a multiplicity of factors, including biological aspects (such as age and 
gender), socioeconomic factors (such as education and SES), and somatic and mental 
syndromes and symptoms (such as chronic diseases and low mood) are associated with 
the occurrence of non-dementia CI. A heterogeneous development of CI is suggested. 
Some of the factors are modifiable and may be prevented or treated, while non-
modifiable correlates and risk factors for CI can help to improve prognosis by 
identifying subjects at risk of accelerated cognitive decline.  
Improvements in the accuracy of estimates of non-dementia CI as well as 
advancements in the understanding of its etiology are of extreme importance both at 
societal and individual levels. Indeed, accurate estimates of CI occurrence can help 
planning of both health care policies and expenditures. On the other hand, a more 
thorough knowledge of the mechanisms underlying MCI development and evolution 
could result in better preventative strategies and prognostic procedures. Whereas 
preventative strategies can reduce the occurrence of CI in the nondementated elderly, 
with important economic consequences, more precise prognostic procedures can 
improve the management of affected people and reduce the psychological burden 
associated to both subjective and objective CI. 
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9 FUTURE DIRECTIONS 
Our estimates of the occurrence of non-dementia CI should be replicated using similar 
criteria across different populations. To reduce the variability of prevalence and 
incidence estimates of CI, steps should also be made towards an increased homogeneity 
in the defining and operationalization criteria of CI syndromes. This aim could be 
primarily achieved by a) devising longitudinal community-based studies focusing on 
the comparative validity, stability, and predictivity of alternative constructs of non-
dementia CI and of different operationalization criteria within the same construct; and 
b) evaluating accumulated evidence in the framework of expert-based consensus 
panels. 
To disentangle the relative contribution of biological, socioeconomic, somatic, 
environmental, and psychosocial aspects to the development and progression of non-
dementia CI, more evidence from longitudinal, community-based, studies is warranted. 
These prospective investigations should allow the comparison of multiple factors, 
which can be achieved by the inclusion of repeated and detailed multi-dimensional 
evaluations including medical, clinical, and genetic information coupled with in-depth 
interviews on environmental and psychosocial exposures. Special attention should be 
devoted to the timing of the different factors that can contribute to the complex etiology 
and variable evolution of non-dementia cognitive impairment. 
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